2018N357118_01 CONFIDENTIA L
ViiV Healthcare group of companies 208832
1TITLE PA GE
Protocol Title: A Phase 1, Open -Label Study  to Evaluate the Pharmacokinetics and 
Tolerability  of Cabotegravir and Rilpivirine L ong-Acting Injections Following 
Intramuscular Administration in the Vastus Lateralis Muscle of Healthy  Adult 
Participants
Protocol Number : 208832/01
Compound Number GSK1265744, GSK1329758
Study Phase: Phase 1
Short Title : Cabotegravir LA and Rilpivirine LA Thigh PK Study
ViiV Healthcare group of companies
US IND Sponsor Name and Legal Registered Address:
ViiV Healthcare Company
Five Moore Drive
P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: + 1 919 438 2100
This study  is sponsored by  ViiV Healthcare.  GlaxoSmithKline is supporting ViiV 
Healthcare in the conduct of this study .  
Medical Monitor Name and Contact Information can be fou nd in the Study 
Reference Manual
Regulatory Agency Identifying Number(s):
IND: 109,678
Approval Date: 13- AUG -2020
Copy right 2020 ViiV Healthcare group of companies.  All rights reserved.  Unauthorized 
copy ing or use of this information is prohibited.
2018N357118_01 CONFIDENTIA L
208832
3PROTOCOL AMENDMENT SUM MARYOF C HANGES TABLE
DOCUMENT HISTORY
Document Date DNG Number
Amendment 1 13-AUG -2020 2018N357118_01
Original Protocol 02-MAR -2020 2018N357118_00
Amendment 1: 13-AUG -2020
Overall Rationale for the Amendment:
Revisions were made to the study  eligibility  criteria and safet y assessments to further 
mitigate the potential risks for study conduct during the COVID -19 pandemic.  
Section # and 
NameDescription of Change Brief Rationale
1.3 Schedule of 
Activities (SOA)SOA revised to include SARS -
CoV-2 testing at Screening and 
onadmission to the Phase I unit 
prior to the oral lead -in phase To mitigate risk to study conduct during 
the COVID -19 pandemic
5.1 Inclusion 
CriteriaParticipant age range revised so 
that no participants >50 years of 
age are includedTo mitigate risk to study conduct during 
the COVID -19 pandemic
5.1 Inclusion 
CriteriaIncluded a new criterion for 
participants to have two 
consecutive negative tests for 
SARS -CoV-2 at Screening and 
on admission To mitigate risk to study conduct during 
the COVID -19 pandemic
5.2 Exclusion 
CriteriaIncluded two new criteria 
excluding partic ipants having 
signs and symptoms suggestive 
of COVID -19 and participants 
who had contact with a known 
COVID -19 positive person/s 
within 14 days prior to admissionTo mitigate risk to study conduct during 
the COVID -19 pandemic
8.1.4. Clinical 
Safety Labora tory 
AssessmentsInformation on screening for 
SARS -Cov-2 includedTo mitigate risk to study conduct during 
the COVID -19 pandemic
8.4 
PharmacokineticsOne additional PK sampling 
timepoint added (Day 1 12h) and 
modification of sampling window 
for Day 1 8h a nd Day 2 PK 
during OLI PhaseSince participants remain at the site 
overnight on Day 1 during OLI, 
additional PK timepoint swas added to 
improve precision of PK parameter 
estimation
11.8. Appendix 8: 
Permissible Investigator(s) should utilise 
WHO Case Definitions to classify To mitigate risk to study conduct during 
the COVID -19 pandemic
2018N357118_01 CONFIDENTIA L
208832
4Section # and 
NameDescription of Change Brief Rationale
Procedures 
during the 
COVID -19 
Pandemic
12.ReferencesCOVID -19 cases [World Health 
Organisation, 2020].
WHO reference included.  
Throughout Minor editorial and document 
formatting revisionsMinor, therefore have not been 
summarized
2018N357118_01 CONFIDENTIA L
208832
5TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.PROTOCOL SUMMARY .......................................................................................... 8
1.1. Synopsis ....................................................................................................... 8
1.2. Schema ...................................................................................................... 10
1.3. Schedule of Activities (SoA) ........................................................................ 11
1.3.1. Screening and Oral Lead -in Phase .............................................. 11
1.3.2. CAB LA + RPV LA Injection Phase and Follow -up...................... 14
2.INTRODUCTION .................................................................................................... 16
2.1. Study Rationale .......................................................................................... 16
2.2. Background ................................................................................................ 16
2.3. Benefit/Risk Assessment ............................................................................ 17
2.3.1. Risk Assessment ......................................................................... 18
2.3.1.1. Other Clinically Relevant Information .......................... 23
2.3.2. Benefit Assessment ..................................................................... 23
2.3.3. Overall Benefit: Risk Conclusion .................................................. 23
3.OBJECTIVES AND ENDPO INTS ........................................................................... 24
4.STUDY DESIGN .................................................................................................... 25
4.1. Overall Design ............................................................................................ 25
4.1.1. Screening .................................................................................... 26
4.1.2. Oral Lead -in Phase ...................................................................... 26
4.1.3. CAB and RPV Injection and PK Sampling .................................... 26
4.1.4. Follow -up/W ithdrawal Visit ........................................................... 26
4.2. Justification for Dose .................................................................................. 27
4.2.1. Oral Dose: ................................................................................... 27
4.2.2. Long Acting Injectable Dose: ....................................................... 27
4.3. End of Study Definition ............................................................................... 29
5.STUDY POPULATION ........................................................................................... 29
5.1. Inclusion Criteria ......................................................................................... 29
5.2. Exclusion Criteria ........................................................................................ 31
5.3. Lifestyle Considerations .............................................................................. 33
5.3.1. Meals and Dietary Restrictions .................................................... 33
5.3.2. Caffeine, Alcohol, and Tobacco ................................................... 34
5.3.3. Activity ......................................................................................... 34
5.4. Screen Failures ........................................................................................... 34
6. STUDY INTERVENTION ........................................................................................ 34
6.1. Study Interventions Administered ............................................................... 35
6.1.1. Formulations of CAB and RPV ..................................................... 35
6.1.1.1. Cabotegravir Tablets (CAB) ........................................ 35
6.1.1.2. Rilpivirine Tablets (RPV) ............................................. 35
6.1.1.3. Cabotegravir Extended Release Suspension 
for Injection (CAB LA) ................................................. 36
2018N357118_01 CONFIDENTIA L
208832
66.1.1.4. Rilpivirine Extended Release Suspension for 
Injection (RPV LA)) ..................................................... 36
6.2. Preparation/Handling/Storage/Accountability .............................................. 36
6.2.1. Dosing Considerations for CAB LA + RPV LA .............................. 37
6.3. Study Intervention Compliance ................................................................... 37
6.4. Concomitant Therapy .................................................................................. 37
6.4.1. Permitted Medications and Non -Drug Therapies.......................... 38
6.4.2. Prohibited Medications and Non -Drug Therapies ......................... 38
6.5. Dose Modification ....................................................................................... 39
6.6. Intervention after the End of the Study ........................................................ 39
7.DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/W ITHDRAW AL..................................................................... 39
7.1. Discontin uation of Study Intervention .......................................................... 39
7.1.1. Liver Chemistry Stopping Criteria ................................................ 40
7.1.2. QTc Stopping Criteria .................................................................. 41
7.2. Participant Discontinuation/W ithdrawal from the Study ............................... 42
7.3. Lost to Follow Up ........................................................................................ 42
8.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 43
8.1. Safety Assessments ................................................................................... 43
8.1.1. Physical Examinations ................................................................ .43
8.1.2. Vital Signs .................................................................................... 44
8.1.3. Electrocardiograms ...................................................................... 44
8.1.4. Clinical Safety Laboratory Assessments ...................................... 44
8.1.5. Suicidal Ideation and Behavior Risk Monitoring ........................... 45
8.2. Adverse Events and Serious Adverse Events ............................................. 45
8.2.1. Time Period and Frequency for Collecting AE and SAE 
Information ................................................................................... 45
8.2.2. Method of Detecting AEs and SAEs ............................................. 46
8.2.3. Follow -up of AEs and SAEs ......................................................... 46
8.2.4. Regulatory Reporting Requirements for SAEs ............................. 46
8.2.5. Pregnancy ................................................................................... 47
8.3. Treatment of Overdose ............................................................................... 47
8.4. Pharmacokinetics ....................................................................................... 47
8.5. Genetics ..................................................................................................... 49
8.6. Patient Reported Outcomes ........................................................................ 49
9. PHARMACOKINETIC METH OD OF ANALYSES ................................................... 49
10.STATISTICAL CONSIDER ATIONS ........................................................................ 50
10.1. Statistical Hypotheses ................................................................................. 50
10.2. Sample Size Determination ........................................................................ 50
10.3. Populations for Analyses ............................................................................ 50
10.4. Statistical Analyses ..................................................................................... 50
10.4.1. General Considerations ............................................................... 51
10.4.2. Primary Endpoint(s) ..................................................................... 51
10.4.3. Secondary and Safety Endpoint(s) .............................................. 52
10.5. Interim Analyses ......................................................................................... 52
11.SUPPORTING DOCUMENTA TION AND OPERATIONAL
CONSIDERATIONS ............................................................................................... 53
2018N357118_01 CONFIDENTIA L
208832
711.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations ............................................................................................ 53
11.1.1. Regulatory and Ethical Considerations ........................................ 53
11.1.2. Financial Disclosure ..................................................................... 53
11.1.3. Informed Consent Process .......................................................... 53
11.1.4. Data Protection ............................................................................ 54
11.1.5. Dissemination of Clinical Study Data ........................................... 54
11.1.6. Data Quality Assurance ............................................................... 55
11.1.7. Source Documents ...................................................................... 56
11.1.8. Study and Site Start and Closure ................................................. 56
11.1.9. Publication Policy ......................................................................... 56
11.2. Appendix 2: Clinical Laboratory Tests ......................................................... 58
11.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 60
11.3.1. Definition of AE ............................................................................ 60
11.3.2. Definition of SAE .......................................................................... 61
11.3.3. Recording and Follow -Up of AE and SAE .................................... 62
11.3.4. Reporting of SAE to GSK ............................................................. 64
11.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 66
11.4.1. Definitions: ................................................................................... 66
11.4.2. Contraception Guidance: ............................................................. 67
11.4.3. Collection of Pregnancy Information: ........................................... 68
11.5. Appendix 5: Genetics .................................................................................. 69
11.6. Appendix 6: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 70
11.7. Appendix 7: Division of AIDS Table for Grading the Severity of Adult 
and Pediatric Adverse Events Version 2.1, March 2017 .............................. 72
11.8. Appendix 8: Permissible Procedures during the COVID- 19 
Pandemic .................................................................................................... 73
11.9. Appendix 9: Abbreviations and Trademarks ................................................ 74
11.10. Appendix 10: Protocol Amendment History ................................................. 77
12.REFERENCES ....................................................................................................... 78
2018N357118_01 CONFIDENTIA L
208832
81. PROTOCOL SUMMA RY
1.1. Synopsis
Protocol Title: A Phase 1, Open- Label Study  to Evaluate the Pharmacokinetics and 
Tolerability  of Cabotegravir and Rilpivirine L ong-Acting Injections Following 
Intramuscular Administration in the Vastus Lateralis Muscle of Health y Adult 
Participants
Short Title: Cabotegravir LA and Rilpivirine LA Thigh PK Study
Rationale: The objective of this study  is to evaluate the pharmacokinetics, tolerability , 
and safet y of cabotegravir ( CAB ) long acting (LA)+ rilpivirine ( RPV )LA administered 
concomitantly  as two separate I M injections in the vastus lateralis muscle of adult 
healthy  participants.  Data from this study will be used to inform the feasibility  of 
administering CAB LA + RPV L A in the vastus lateralis muscle in HI V-infected 
children < 12 years of age and adult populations.   
Objectives and Endpoints:
Objectives Endpoints
Primary
ï‚·To describe the PK profiles of 
CAB and RPV following a 
single intramuscular injection 
each of CAB LA + RPV LA 
administered to the lateral thigh 
muscle in adult healthy  
participants ï‚·Maximum observed concentration 
(Cmax) and time of maximum observed 
concent ration (tmax) in plasma
ï‚·Area under the concentration â€“ time curve 
from time zero to last quantifiable time 
point (AUC(0- t)) through the follow -up 
phase
ï‚·Area under the concentration â€“ time curve 
from time zero to infinity  (AUC0 -ï‚¥)
ï‚·Apparent terminal phase ha lf-life (tÂ½) 
and absorption rate constant (KA LA))
Safety
ï‚·To assess safety  and tolerability  
of CAB and RPV following 
repeated oral dose and single 
intramuscular injection in the 
lateral thigh of healthy  
participantsï‚·Safety  and tolerability  parameters including 
adverse events (AEs) , clinical laboratory  
tests, electrocardiogram (ECG ), and vital sign 
assessments
2018N357118_01 CONFIDENTIA L
208832
9Overall Design:
This is a Phase 1, open label study conducted in healthy  participants to assess the PK of 
CAB and RPV in plasma following a single 600 mg (1 x 3 mL ) and a 900 mg (1 x 3 mL )
injection each,respectively , administered IM to separate vastus lateralis muscles on each 
leg. 
The COVID -19 pandemic presents significant logistical challenges for many  clinical sites 
around the world, wit h variable restrictions being placed on site resources and operations, 
and on an individual participantâ€™s ability  to attend clinic visits.  Based on these 
challenges, it may  be necessary  to adopt additional measures and procedures to protect 
participant sa fety, and to allow flexibility  to allow conduct of the study .  
Number of Participants:
Approximately  15adult healthy  participants w illbe dosed with injectable study  
interventions. If participants prematurel y discontinue the study ,for an y other reason ,
other than an AE ,additional replacement participants may  be enrolled at the discretion of 
the Sponsor in consultation with the investigator.
Approximately  30% of female participants will be enrolled.
Intervention Groups and Duration:
The study  will consist of 
ï‚·30-day screening period
ï‚·28-day oral lead-in(OLI) phase at a CAB dose of 30 mg and RPV dose of 25 mg 
once a day  with a meal 
ï‚·10 â€“ 14 days washout period
ï‚·CAB and RPV injection, administered IM: 600 mg (1 x 3 mL ) CAB on left and a 
900 mg (1 x 3 mL )RPV injection on right vastus lateralis muscle 
ï‚·Sparse PK sampling for up to 29 days in OLI and serial PK sampling for up to 4 
weeks after the injection , per SoA. Participant s will return for safet y assessments 
and additional PK sampling at Week 8, 12, 24, 36, and 52 post last injection during 
the follow- up phase.
Data Monitoring or other Committee: No
2018N357118_01 CONFIDENTIA L
208832
101.2. Schema

2018N357118_01 CONFI DENTIA L
208832
111.3. Schedule of A ctivities (SoA )
The timing and number of planned study  assessments, including as outlined in the SoA below, including safet y and pharmacokinetic or 
other assessments may  be altered during the course of the study  based on newly  available data (e.g., to obtain data closer to the time of 
peak plasma concentrations) and to ensure appropriate monitoring.
Any changes in the timing or addition of time points for any  planned stud y assessments must be documented and approved by  the relevant 
study  team member and then archived in the Sponsor and site study  files but will not constitute a protocol amendment. The IRB/IEC will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme or amendment of the informed consent form
(ICF).Appendix 8 summarises permissible procedures during the COVID -19 pandemic (Section 11.8). 
1.3.1. Screening and Oral Lead -in Phase
Study Period
Screening1Oral Lead- in9
Day 29Early 
Withdrawal9Washout Period
Dosing Days 1 -28
Visit Window  Within
30 days
of oral 
lead-inDay -1
Day 1 Day 2 Day 14Within 24 
hours of the 
Day 28 last 
doseEW 10 â€“ 14 days
Informed Consent X
Demographics X
Medical / Medication / 
Drug / Alcohol HistoryX
Inclusion/Exclusion 
Criteria2 X X
Height, Weight, BMI X
Physical Exam X X
Vital Signs3 X X X X X X
12-Lead ECG X X X
Drug / Alcohol Screen3 X X
2018N357118_01 CONFI DENTIA L
208832
12Study Period
Screening1Oral Lead- in9
Day 29Early 
Withdrawal9Washout Period
Dosing Days 1 -28
Visit Window  Within
30 days
of oral 
lead-inDay -1
Day 1 Day 2 Day 14Within 24 
hours of the 
Day 28 last 
doseEW 10 â€“ 14 days
Pregnancy Test3 X X X X
Testing for SARS -CoV-24 X X
Hepatitis B, Hepatitis C 
ScreeningX
HIV Test X
Urine Dipstick X
Hematology with 
differential; Clinical 
Chemistry Tests3X X X X X X
Coagulation Tests X
Admit to clinic X
Dispense Oral lead -in IP X
Administer oral CAB + 
RPV5 X X X
Dispense Medication 
Dosing DiaryX
Drug accountability/ pill 
count/review drug diaryX X X
Blood plasma PK 
sampling6X X X X X
AE Assessment7 X X X X X
Concomitant Medication 
ReviewX X X X X
Genetic sample8 X
Discharge from the clinic X
1. Screening may occur over more than one visit but within 30 days of the first dose of oral CAB and RPV in the oral lead in phase.
2018N357118_01 CONFI DENTIA L
208832
132. Eligibility criteria must be carefully assessed at the Screening visit and confirmed at the Day 1 Oral lead -in phase visit and re -confirmed prior to injection.
3. Prior to administering the first oral dose of CAB and RPV, study personnel must verify the following pre -dose assessments to be within normal limits prior to administration: vital 
signs, pregnancy test (negative; F emales of Reproductive P otential(FRP) only . The results of the Drug/Alcohol screen, hematology with differential, and clinical chemistry tests on 
Day 1 are not required prior to administering the first oral dose sof CAB and RPV but should be drawn prior to CAB and RPV administration .
4. Two consecutive approved molecular tests (PCR or antigen test) must be conducted on all study participants and separated by > 48hours. Following the second test for SARS -
CoV-2, participants should be quarantined within the unit. Once the second test is negative, the participant can be released into the unit and follow Infection Control practices   
5. Oral CAB and RPV dosing Days 1 to 28. Day 1, Day 2, and Day 14 doses should be administered in the clinic.  
6. PK sampling â€“On Day 1 -1h, 2h, 3h, 4h, 6h , 8h, a nd 12h, and Day 2 PK between 22 to 26 h post first oral dose . On Day 14 pre -dose samples. Day 29 PK should occur between 
22 to 26 hours from the last dose on Day 28 . Total of 20 PK samples ( 10for CAB, 10 for RPV assay) will be collected during oral lead -in phase. Please refer to Section 8.4for 
permitted PK window for OLI phase.
7. AE assessment will include a brief, symptom -directed physical exam as needed.
8. Genetic sample -collect the sample at the earliest convenient time after t he first dose in the oral lead in phase on Day 1.
9. If aparticipant is withdrawn prior to receiving the CAB LA and/or RPV LA injection, a follow- up/withdrawal visit should be scheduled 10 -14 days after the last oral dose of CAB and 
RPV.
	
 	

	

)*-*,*  (
3# 
4 .52

5'"6%%.* 
'
5
&(&,&3&7&89/&(2&(7&(8&,,&,/
:-;3<-;/-;(,-;,3-;1=-;7,-".%(
"


		1	E	)D	D2	
'..!'>%%8		$
J*!J,!J	J	J	J	J	J	J	J	J	J 'J 'J 'J 'J '

%99#9
?%"%&,>
'#& > > >>>>>>
(,*)	, >> > >>

0 > > >>
%#&@%%"& > > > > >>>>>>
0%#, > > >>>>>> > >>>>>>
??$)?A'0)?, >
>>>>>
>

5 >>>>>>>>>> > >>>>>>
?	?3 >>> >>>>>>> > >>>>>>
B. > >>>>>>>>>> > >>>>>>
$% %'> %#7 >>>>>>>>>>> > >>>>>>
" $  -	
! 
4

-

&*-

4
 &
 
	

 -	 - 
CCI
	
 	

	

( '6'$


!
'	


-$
 
 
!
4
-	! 

!$F
7. @6 
6$
 '

 
BG"
'6

-
. 
!
6 ! !
 # 
 
 4 ! 
'6 
 

' .6$	4
!
 	  $


F
4

0

6	
!
 

!!4
 
	

" $ -

4
 &

4
	
!


- 		
F



 

1. 
!
-



 4
6'!$!

$	' 

/ ! 



* % 
1 "5 !$
E 
 	? "-

4


 
		?3C"3#F
"	 
 G

-$CCI
CCI
2018N357118_01 CONFIDENTIA L
208832
162. INTRODUCTION
2.1. Stud y Rationale
Cabotegravir (CAB) is an integrase inhibitor being developed in combination with 
rilpivirine (RPV, TMC278), a non-nucleoside reverse transcriptase inhibitor, for the 
treatment of HIV. CAB is currently  in Phase 3 development as monotherap y for the 
prevention of sexually -acquired HIV-1 infection.  CAB and RPV are separately  formulated 
as oral tablets for once daily  administration and as long -acting (LA) aqueous suspensions 
for parenteral administration monthly  or every 2-months.  RPV 25mg oral tablets is 
approved as EDURANT in multiple countries, including the USA, Europe and Canada, for 
use in antiretroviral (ARV) treatment -naÃ¯ve patients.   
A two -drug long-acting, monthly  antiretroviral regimen of CAB + RPV has demonstrated 
good efficacy , tolerability , and long -term safet y in HIV -infected adults following oral and 
monthly  and every  2-month IM do sing in the gluteus muscle for durations exceeding 3 
years in Phase 2 and Phase 3 studies [LATTE , 2019; LATTE -2, 2018; ATLAS , 2019; 
FLAIR , 2019, ATLAS -2M, 2018]. R eview and approval of the CAB + RPV regimen for 
treatment of HIV infection is ongoing.     
Separate early  Phase 1 studies of CAB LA and RPV LA evaluated PK and tolerability  of 
single and repeat -dose injections in other anatomic locations including abdomen 
(subcutaneous) and IM administration in the ventrogluteal muscle (CAB ), gluteus maximus 
muscle (RPV ), and deltoid muscle (RPV )in healthy  volunteers [HIV Therap y, 2013; 
International AIDS S ociety , 2013; RPV LA NATAP report , 2008 ].  Gluteal injections of 
CAB L A + RPV LA were progressed in late-stage studies given better participant
tolerability  to injections at this injection site with the anticipated injection dosing volume 
required to achieve desired exposures.  
There remains considerable interest in exploring alternative injection sites either as an 
alternative rotational (e.g. gluteal injection fatigue) or chronic injection site (e.g. gluteal 
implants contraindicating injection or young pediatric populations without sufficient 
gluteal mass for injection).  The vastus lateralis muscle in the thigh has been used as an 
injection location for other drugs (e.g. epinephrine, etc .) and is a common injection site in 
young children (e.g. vaccines). Moreover, self-or partner-injection of CAB LA + RPV LA 
in the thigh muscle may  be explored in future studies pending favorable pharmacokinetics, 
safet y, and tolerability of CAB LA + RPV LA thigh injections. 
The objective of this study  is to evaluate the pharmacokinetics, tolerability, and safet y of 
CAB LA + RPV LA administered concomitantl y as two separate IM injections in the vastus 
lateralis muscle of adult healthy  participants.  Data from this study  will be used to inform 
the feasibility  of administering CAB LA + RPV LA in t he vastus lateralis muscle in HIV -
infected children <12 years of age and adult populations.   
2.2. Background
The treatment of HIV-1 infection has advanced since the first oral antiretroviral agent 
(AZT) was approved for the treatment of HIV-1 infected individ uals in 1987. Newer 
2018N357118_01 CONFIDENTIA L
208832
17antiretrovirals are more potent, better tolerated and have enabled the formulation of 
multiple regimens that can provide viral suppression with a single tablet once dail y. 
Long acting injectable versions of drugs are being developed toenable therapy  with 
infrequent dosing schedule. These therapeutic options hold great promise for future 
treatment and represent an emerging paradigm for the treatment of HI V infection. CAB is 
a potent integrase inhibitor that possesses attributes that allow formulation and delivery as 
a long-acting parenteral product. RPV is a diary lpyrimidine derivative and a potent non-
nucleoside reverse transcriptase inhibitor (NNRTI) with in vitro activity  against wild ty pe 
HIV-1 and select NNRTI -resistant mutants. A t wo-drug regimen with CAB L A plus RPV 
LA (CAB + RPV LA) offers many potential advantages over daily oral regimens including 
infrequent dosing that decreases the daily  reminder to patients of their HIV status, better 
tolerability , less likel y to develop vira l resistance due to intermittent compliance with oral 
agents that can lead to sub-therapeutic concentration of antiretroviral medication and 
emergence of resistance, and improved adherence and overall treatment satisfaction in 
virologicall y suppressed pati ents. Results to date have demonstrated the efficacy of a two -
drug regimen of CAB + RPV LA as maintenance therap y with several on-going Phase 2 
and 3 studies including LATTE -2, ATLAS, FLAIR, and ATL AS 2M currently  underwa y 
[ATL AS, 2019; FLA IR, 2019 ]
As of 18-Oct-2018, in the Phase 3 Study  201584, a total of 283 HIV-infected subjects have 
received CAB 30 mg once daily  with RPV 25 mg once dail y as oral lead -in (OLI) therap y 
prior to initiation of injections. Of these subjects, 278 have received CAB LA + RPV LA 
gluteal injections (dosed every  4 weeks, Q4W) during the Maintenance Phase of the study. 
In Phase 3Study  201585, a total of 308 HIV-infected subjects entered the Maintenance 
Phase and received CAB 30 mg once daily  and RPV 25 mg once daily as OLI therapy  prior 
to initiation of gluteal injections. Of the 308 subjects who received OLI, 303 transitioned 
to receive CAB + RPV LA injections (dosed Q4W). Of the 308 subjects that entered the 
Maintenance Phase, 282 successfully  completed and 26 subjects withdrew. A pooled 
analysis of the Pha se 3studies demonstrated that monthly  injections with CAB + RPV LA 
were non-inferior to daily oral antiretroviral therapy  for the key virologic endpoints at week 
48. Low confirmed virologic failure was seen across both treatment arms. Injection site 
react ions in the LA arm were mainly  Grade 1 or 2 but with few associated discontinuations.
To date, Phase 2and Phase 3studies of CAB LA + RPV LA have utilized the gluteus 
medius injection sitein HIV-1 patients .  This stud y aims to evaluate alternate injectio n site 
of thigh muscles for CAB LA + RPV LA administered ininjection per each thigh muscle, 
at the same visit.   
2.3. Benefit/Risk A ssessment
More detailed information about the known andexpected benefits and risks and reasonabl y 
expected adverse effects of CAB and RPV may be found in the [CAB IB2019;  
GlaxoSmithKline Document Number RH2009/00003/09; RPV IB , 2019 ].
2018N357118_01 CONFIDENTIA L
208832
182.3.1. Risk A ssessment
Potential Risk of 
Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Drug Induced Liver 
Injury (DILI)A small proportion of participants in the 
CAB program to date (total exposure 
>3100 participants) have developed 
transaminitis (elevated liver 
transaminases characterized by 
predominant alanine aminotransferase 
(ALT) elevation).  In most participants, 
transient transaminitis was explained by 
acute viral hepatitis infection (.  In a 
small number of participants, there was 
not an alternative explanation, 
suggesting a mild form of drug induced 
liver injury (DILI) without hepatic 
dysfunction, which resolved upo n 
withdrawal of treatment with CAB. 
All participants with suspected DILI 
identified to date were receiving oral 
CAB.  ï‚· Exclusion criteria as described in 
Section 5.2will prohibit participation 
with significant liver impairment based 
on screening liver chemistry including 
transaminases (ALT and Aspartate 
aminotransferase [AST]) as well on 
prior medical history.
ï‚· A 4-week oral lead -in Phase is being 
implemented in this study, where all 
participants will receive oral CAB prior 
to the administration of IM CAB to 
assess individual safety and tolerability 
Liver transaminases (ALT and AST) 
will be monitored throughout this study 
(refer to Schedule of Activities) and the 
liver chemistry stopping criteria will be 
adopted as described in Section 7.1.1
of this protocol. 
ï‚· All instances of liver transaminase 
elevations of Grade 2 and above wil l 
be followed to resolution. Participants 
withdrawn from the study due to 
meeting liver chemistry stopping 
criteria will be regularly monitored both 
clinically and using liver chemistries to 
determine progress towards resolution 
of the liver event.
Effects in late stage 
pregnancy seen in 
non- clinical studiesIn animal reproduction studies, CAB 
when administered to rats at > 30 times 
the systemic exposure at the maximum 
recommended oral human dose 
(MRHD) of 30 mg during organogenesis 
through delivery, had adverse effects on 
labor and delivery that may be related 
to a delay in the onset of parturition, 
resulting in increased fetal mortality 
(stillbirths) and neonatal deaths 
immediately after birth.
The clinical significance of these finding 
in humans is unknown.ï‚· As a routine precaution, pregnant 
women are excluded from participation 
in this study and females of 
reproductive potential (FRP) are 
required to adopt highly reliable means 
of contraception during participation 
and throughout the long term fol low up 
phase of this study following exposure 
to CAB LA.
ï‚· FRP are also required to undergo 
regular pregnancy testing throughout 
study conduct to enable early 
discontinuation of CAB LA if 
pregnancy is identified.
2018N357118_01 CONFIDENTIA L
208832
19Potential Risk of 
Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Potential effects in 
women exposed to 
dolute gravir during 
conception and early 
pregnancyA preliminary analysis of an ongoing 
birth outcome surveillance study in 
Botswana involving women exposed to 
dolutegravir (DTG) a different molecule 
in the same integrase class of 
medications as CAB, identified four 
cases (as of May 2018) of neural tube 
defects in 426 infants born to mothers 
who were exposed to DTG -containing 
regimens from the time of conception. 
In the same study, no infant born to a 
woman who started DTG during 
pregnancy had a neural tube defec t, out 
of 2,824 women. A causal relationship 
of these events to the use of DTG has 
not been established. The incidence of 
neural tube defects in the general 
population ranges from 0.5 -1 case per 
1,000 live births. As neural tube defects 
occur within the fi rst 4 weeks of fetal 
development (at which time the neural 
tubes are sealed) this potential risk 
would concern women exposed to DTG 
at the time of conception and in early 
pregnancy.
The clinical relevance of either of these 
findings in relation to CAB use is 
unknownï‚· As a routine precaution, pregnant 
women are excluded from participation 
in clinical trials of CAB at this time and 
females of reproductive potential 
(FRP) are required to adopt highly 
reliable means of contraception during 
participation and thr oughout long term 
follow up phases of studies after 
exposure to CAB and RPV LA.
ï‚· Females of reproductive potential also 
undergo regular pregnancy testing 
throughout study conduct to enable 
early discontinuation of study drugs 
once pregnancy is identified. However, 
it should be noted that CAB 
concentration could remain for 
prolonged periods despite 
discontinuation of CAB LA .
Drug -Drug 
Interactions (DDIs)For a complete listing of permitted and 
prohibited concurrent medications for 
CAB,CAB LA, RPV and RPV LA, refer 
to Section 6.4.ï‚· All participants will be informed of 
prohibited medications throughout the 
study and updates provided as needed 
via the informed consent.
Injection Site 
Reactions (ISR)There are extensive safety and 
tolerability data, including ISRs
following IM administration of CAB LA 
and RPV LA. Please refer to each IB 
for additional information [CAB IB 
GlaxoSmithKline Document Number 
RH2009/00003/09 , RPV IB , 2019 ]ï‚· Administration advice to minimize risk 
of poor administration technique givi ng 
rise to injection site reactions. Advice 
on care, monitoring, natural course, 
and treatment of ISRs given in study 
documentation 
ï‚· Advice to participants on care of 
injection site on day/days immediately 
post administration, use of analgesia, 
compresses where appropriate.
ï‚· Participants will be closely monitored 
for ISRs particularly for signs of pain, 
tenderness, infections, erythema, 
swelling, induration, or nodules 
(granulomas or cysts) throughout the 
study. 
ï‚· Complications of ISRs such as 
infections (ab scess, cellulitis) and 
2018N357118_01 CONFIDENTIA L
208832
20Potential Risk of 
Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
collections of fluid requiring drainage 
will be monitored 
ï‚· Significant ISRs may be photographed 
and referred to a dermatologist for 
specialist advice.
Rash Some observations of rash with oral 
RPV have been reported in clinical 
studies executed to date (the majority 
are mild). 
Severe skin and hypersensitivity 
reactions have been reported during the 
post- marketing experience with oral 
RPV-containing regimens, , including 
cases of Drug Reaction with 
Eosinophilia and Systemic Symptoms 
(DRESS).  While some skin reactions 
were accompanied by constitutional 
symptoms such as fever, other skin 
reactions were associated with organ 
dysfunctions, including elevations in 
hepatic serum biochemistries.ï‚· Participants with a Grade 1 or 2 rash 
will be allowed to continue treatment or 
to be rechallenged, depending on the 
clinical judgment of the investigator.
ï‚· All participants developing a Grade 3 
or 4 rash should discontinue  st udy 
drugs and be withdrawn from the 
study.
ï‚· All rash events should be assessed 
with special attention to systemic 
symptoms, laboratory abnormalities, or 
mucosal involvement. Close clinical 
follow -up, including follow- up of 
laboratory abnormalities, and 
appropriate medical intervention, 
including referral to dermatologist as 
appropriate, should be instituted for 
these events; daily follow- up is 
recommended for 5 days from the 
onset of the event to monitor for 
progression of the event. In case of 
cutaneous reaction/rash and/or an 
allergic reaction, the use of cetirizine, 
levocetirizine, loratadine, 
diphenhydramine, topical 
corticosteroids, or antipruritic agents is 
permitted.
2018N357118_01 CONFIDENTIA L
208832
21Potential Risk of 
Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Inadvertent 
Intravenous Injection 
(Accidental 
Maladministration)As with any intramuscular injection, it is 
possible that CAB LA and/or RPV LA 
can be inadvertently administered 
intravenously instead of intramuscularly 
possibly resulting in higher than 
expected concentrations of CAB and/or
RPV shortly after injection and lower 
concentrations thereafter. This could be 
due to administrator error, improper 
injection technique and / or improper 
needle length used based on body type.  ï‚· Training will be provided to all sites on 
proper injection technique.
ï‚· Should IM maladminist ration be 
suspected at any time (e.g., suspected 
under or overdose or inadvertent 
intravenous [IV] dosing), post dose 
ECG monitoring and vital signs or any 
other supportive testing may be 
obtained at the discretion of the 
investigator, and the medical monitor 
notified.
ï‚· 2-hour post dose PK samples will be 
for determination of CAB and RPV 
concentration and possible 
pharmacokinetic correlation with safety 
parameters such as ECG changes. 
Hypersensitivity 
Reactions (HSR)Hypersensitivity reactions have been 
reported as uncommon occurrences 
with integrase inhibitors (INI), including 
the closely related compound 
dolutegravir, and were characterized by 
rash, constitutional findings, and 
sometimes, organ dysfunction, including
liver injury. 
While there have been no clinical cases 
of hypersensitivity to CAB to date, there 
is a theoretical risk of systemic or 
severe hypersensitivity reactions with or 
without hepatic symptoms associated 
with use of IM CAB. The long 
exposures anticipated after IM CAB 
injection may complicate the 
management of a drug hypersensitivity 
reaction, were it to occur.ï‚· The risk of developing a 
hypersensitivity reaction post 
administration of CAB and RPV will be 
minimized by the use of a 4 -week oral 
lead-in of oral CAB/RPV to determine 
individual safety and tolerability prior to 
the introduction of IM CAB.
ï‚· Clinical assessments, laboratory tests 
(including liver transaminases) and 
vital signs will be performed 
throughout this study. Results from 
these assessments may aid early 
detection of HSR. 
ï‚· Oral CAB will be withdrawn 
immediately for cases with suspected 
HSR during the oral CAB/RPV lead- in 
phase and participants would not 
proceed to the injection phase. Any 
HSR reactions that occur would be 
managed sup portively.
New site of 
intramuscular 
injection: vastus 
lateralisIntramuscular CAB injections into the 
thigh ( vastus lateralis ) have not 
previously been administered in the 
CAB development program. Similar to 
the ventrogluteal region, the vastus 
lateralis is free of major nerves and 
blood vessels. Therefore, it is expected 
to be a safe site for injections. The 
vastus lateralis is part of a large muscle 
group and can tolerate high volume 
injections of up to 5ml  [Rodger , 2000]
in adults with lesser amounts being 
stipulated in younger participants or in 
those with less developed or atrophied 
muscle beds [Rodger , 2000]ï‚· Training of the appropriate technique 
will be provided to staff at the study 
centre and will be described in the 
study manual
ï‚· During the injection phase further 
enrolment and dosing of participants 
may be stopped if a participant 
develops a â‰¥Grade 3 related AE 
(including thigh injection site 
complications) .
2018N357118_01 CONFIDENTIA L
208832
22Potential Risk of 
Clinical 
SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Venipuncture Participants will be required to have 
blood samples taken , which entails, risk 
of bruising, and rarely, infectionï‚· Trained personnel will perform 
venip uncture .
Risks of ECG pad 
removalSome discomfort and rash may occur 
where the ECG pads are applied and 
subsequently.ï‚· ECGs will be conducted by 
appropriately trained personnel and 
effort made to minimize contact time 
for application of the pads.
Vasovagal reaction Receiving injections can cause some 
participants to feel lightheaded or feel 
like they might pass out, or â€˜faintâ€™.  This 
reaction, called a â€˜vasovagal reactionâ€™, 
can occur with many medical 
procedures and resolves quickly.ï‚· The particip ants are monitored and 
stay in the clinic for 2 hours after the 
injection for additional sampling and 
further observation.
2018N357118_01 CONFIDE NTIA L
208832
232.3.1.1. Other Clinically  Relevant Information
Additional details concerning safet y observations from clinical studies and for which a 
causal association has not been established or which are of minimal clinical significance 
may be found in the Investigatorâ€™s Brochures. Refer to â€˜Summary of data and gu idance for 
the investigatorâ€™.
Seizure
Several cases of seizure have occurred during the CAB program. These cases have had 
alternative explanations for their occurrence. Overall, there is not convincing evidence that 
CAB exposure may be causall y associated with seizure or with reduction of seizure 
threshold, due to the low frequency  of reports, the confounders present in the cases received 
to date and lack of any pre-clinical signal or identified plausible mechanism. However, 
seizure and seizure -like events are considered as AEs of special interest for CAB. 
Participants with an unstable or poorly  controlled seizure disorder will be excluded from 
study  participation. Report any cases of seizure or seizure like events within 24 hours of 
the event.
2.3.2. Benefit A sses sment
Participants participating in this study  will not receive an y clinical benefit but will be 
compensated for their time and participation.
Benefit considerations may  include satisfaction from knowledge that participants have 
contributed to the process of developing new therapies for HIV.
2.3.3. Overall Benefit: Risk Conclusion
Review of the cumulative safet y data on CAB and RPV have not identified any safety 
signals which are considered to pose an unacceptable risk to health y participants.
Considering the multiple and overlapping measures that will be taken to minimize risk to 
participants participating in this study , the potential risks identified in association with 
CAB and RPV are justified b y the anticipated benefits that may be afforded to participants 
including the satisfaction of contributing to the ongoing continued clinical development of 
CAB and RPV for both the treatment and prevention of HIV infection.
2018N357118_01 CONFIDE NTIA L
208832
243. OBJECTIVES A ND ENDPO INTS
Objective s Endpoint s
Primary
ï‚·To describe the PK profiles of 
CAB and RPV following a single 
intramuscular injection each of 
CAB LA + RPV LA administered 
to the lateral thigh muscle in adult
healthy  participants ï‚·Maximum observed concentration 
(Cmax) and time of maximum 
observed concent ration (tmax) in 
plasma
ï‚·Area under the concentration â€“ time 
curve from time zero to last 
quantifiable time point (AUC(0 -t)) 
through the follow- up phase
ï‚·Area under the concentration â€“ time 
curve from time zero to infinity  
(AUC0 -ï‚¥)
ï‚·Apparent terminal phase ha lf-life (tÂ½) 
and absorption rate constant (KA LA))
Safety
ï‚·To assess safety  and tolerability  
of CAB and RPV following 
repeated oral dose and single 
intramuscular injection in the 
lateral thigh of adult healthy  
participantsï‚·Safety  and tolerability  parameters 
including adverse events, clinical 
laboratory  tests, ECG, and vital sign 
assessments 
	
 	

	

45/ 6
68	
9* "'	$	
"!
9*)* /	
  
	

			

 		3!"B
$)
!(##	4..#A 
>0C8..#A
 >0C&	
	M	
				%*	
	 

 			#:
 	(!
0.		#
	
-/	A%C
	"B	!0.#$) 	!-5#
	(	

.E
7(
	
"B$)&			%*,4..#A
 >0C"B 	!
8..#A
>0C$)&	# 

 	

	3
#!
-8%	3
 #!
7
(		!		&	
	:
(	! !			
 3
#J		/
--7045-
 &	#
	!(

	:


>	
5	

(		( &		
		:%!


				 !		
		
		

		 			!
	
(		#:

>	0.I!!		

(			:CCI
2018N357118_01 CONFIDE NTIA L
208832
264.1.1. Screening
All participants will undergo a screening visit within 30 days of the first dose of the oral 
lead-inphase . Participants may be rescreened once. Participant s who are enrolled into the 
trial and subsequently  withdrawn from the study , for any reason, may not be re-screened. 
Participants may continue to the oral lead-in phase as soon as all eligibility requirements 
have been met.
4.1.2. Oral Lead -in Phase
Participants that are eligible to participate will be admitted to the clinic on Day 1 of the 
OLI phase and receive their first oral dose of CAB 30 mg and RPV 25 mg with a standard 
breakfast after the completion of all pre-dose assessments. Participants will undergo sparse
PK sampling of blood as described in Schedule of Activities (SoA). After a pre-dose 24-
hour PK sample collection and laboratory  assessment s, participants will take their Day 2 
study  interventions with a meal at the clinic. Participant s will be dispensed a sufficient 
supply  of oral CAB + RPV tablets to complete 26 days of once dail y dosing at home (with 
exception of the visit days at the clinic) and be counseled to take their dose with a meal at 
about the same time each day , before getting dis charged on Day  2. 
On Day 14 of the OLI phase, the participants will return to the clinic. A pre-dose PK sample 
will be collected. In addition, this visit will include assessment of safety , tolerability , and 
participant adherence to study  drug. Participant s should bring their suppl y of oral CAB + 
RPV to the Day 14 visit to have drug accountability  performed. Participants will receive 
Day 14 dose at the clinic.
Participants will return to the clinic on Day  29, within 24 hours of last dose on Day  28 for 
PK, drug accountability , and all assessments performed as described in the SoA Section
1.3. The participants will begin a wash -out period of 10-14 days, during which no CAB 
and RPV will be administered.
4.1.3. CAB and RPV Injection and PK Sampling
After thewashout period of 10 -14 da ys, participants will return to the clinic and receive an 
intramuscular injection of CAB LA (3 mL; 600 mg) on one lateral thigh and RPV LA (3 
mL; 900 mg) into opposite lateral thigh on Injection Phase Day 1. Participants will remain 
in the research unit for at least 4 hours after the injection for PK sampling and safet y 
assessments. Participants will return to clinic for PK sampling and safet y assessm ents for 
4 weeks as outlined in SoA.
4.1.4. Follow -up/Withdrawal Visit 
Because of the long acting PK profile of CAB LA + RPV L A, every  effort should be 
made to bring participant s back in through the 52 weeks post injections. Participant s,who 
received CAB LA + R PV LA IM injection , will return to clinic for safet y and PK 
assessments at Weeks 8, 12, 24, 36, and 52 post IM injections. 
2018N357118_01 CONFIDE NTIA L
208832
27If aparticipant is withdrawn:
ï‚·prior to receiving the IM injection, then a follow -up/withdrawal visit should be 
scheduled 10- 14 da ys after the last oral dose of CAB + RPV. 
ï‚·after receiving IM dose of CAB LA and/or RPV LA injections, every  effort 
should be made to bring the participants back in for the 52 weeks of safet y and 
PK assessments following the injection(s) , because of the long acting PK profile 
of CAB and RPV . 
4.2. Justification for Dose
4.2.1. Oral Dose:
The risk of developing a hy persensitivity  reaction (HSR ),post administration of CAB LA 
and RPV LA is minimized by  the use of a 4 -week OLI of oral CAB and RPV . In the event 
of asuspected HSR ,participants will not receive CAB LA and RPV LA injections . The 
management of participants with HSRs following receipt of drugs with a long half-life may 
be challenging . HSR shave been reported as uncommon occurrences with integrase CAB 
and RPV ,and were characterized by rash, constitutional findings, and sometimes, organ 
dysfunction, including liver injury . The time of onset of HSR reactions supports the 
proposed duration of the OLI with the majorit y of HSRs occurring within the first 28 days 
ofexposure to the drugs.
During the OLI phase of this study , oral formulations of CAB + RPV will be co-
administered to assess safety  and tolerability  in each participant prior to IM dosing with 
CAB LA and RPV LA. The combination of oral RPV 25 mg QD and CAB 10, 30, and 60
mg QD has been used as OLI in HIV -1 infected participants in both Phase IIb studies, the 
pivotal Phase 3 studies (FLAIR and ATLAS) ,and Phase 3 b study  ATLAS -2M. 
In these studies, all three oral CAB doses demonstrated similar efficacy  at the Week 48 
primary  endpoint. However, 30 mg dose was selected as OLI for all CAB LA studies, as it 
delivered higher steady -state exposure s than predicted for the monthly  or every  2-month 
regimen. CAB 30 mg is also the OLI treatment intended for marketing. Therefore, CAB 
30mg along with marketed dose of RPV 25 mg (EDURANT) will be used as the OLI 
dosing in this study  and will achieve expo sures sufficientl y high to assess safety  and 
tolerability  during a short OLI prior to a single IM injection of CAB LA + RPV LA 
formulations.
The PK collected during the OLI phase will be utilized along with the data from LA 
injection phase to precisel y estimate PK parameters using a robust population PK (PoPPK) 
model. A window of 10 to 14 days (covering ~7-10 half-lives) will be used for wash -out 
period prior to LA injection accounting for variability  in half-life in participant s. This 
wash -out period would prevent plasma concentrations after oral administration from being 
mixed with plasma concentrations on Day  1 after LA IM injection. 
4.2.2. Long A cting Injectable Dose:
Thisstudy  will evaluate the intramuscular administration of CAB LA (3 mL; 600 mg) and 
RPV LA (3 m L; 900 mg) into the lateral thigh muscle of left leg and right leg respectivel y.  
2018N357118_01 CONFIDE NTIA L
208832
28The CAB LA + RPV LA Q4W regimen demonstrated noninferiorit y to oral standard of 
care (SOC) in pivotal Phase 3studies.  In those studies, gluteal injections were initiated 
with CAB LA 600mg + RPV LA 900mg (3mL each) followed by monthly  injections of 
CAB LA 400mg + RPV LA 600mg (2mL each). Anevery  2-month dosing regimen of 
CAB LA 600 mg + R PV LA 900 mL is under investigation (3 mL of each drug for all 
injections) .  It is anticipated that absorption from the lateral thigh will be similar to gluteal 
and thus the current study will evaluate the intramuscular administration of CAB LA (3 
mL; 600 mg) and RPV LA (3 mL; 900 mg) into the lateral thigh muscle of left leg and 
right leg respectivel y. Therefore, the terminal slope following the injection (lambda z) is 
expected to be similar in this study  to population PK predictions of absorption rate constant 
(KALA) for CA B [overall population: 0.00064 hr-1(0.0002, 0.0018)] and RPV [ 0.000145
h-1 (0.0001 4 â€“ 0.00016)]. In addition, CAB and RPV concentrations for the current study  
are expected to fall within the range of concentrations observed following the first 
injections in the pooled FLAI R and ATLAS studies.
The following table lists the median, 5th, and 95thpercentiles of evaluable trough 
concentrations of CAB and RPV following initial gluteal 3mL injections from ATLAS 
and FLAIR studies. Furthermore, exposure parameter s are anticipated to fall within the 
range of the model predictions following a single 3 mL gluteal IM injection as shown in 
Table 2. 
Table 1 Observed Trough Concentrations Follo wing First IM Injection in 
FLAIR and A TLAS Studies, Pooled Data
VISIT ANALYTE 5th 50th 95th 
WEEK 4 CAB 0.4521 1.57 3.5
WEEK 4 RPV 17.4 39.45 88.275
Table 2 Model Predicted Exposure Parameters of CA Band RPV Follo wing A  
Single IM Injection in Gluteus Medius
Parameter Units CAB RPV
Median (90% PI) Median (90% PI)
KALA /h 0.00064
(0.0002, 0.0018)0.000146 
(0.000145, 0.00016 4)
Half-Life Weeks 6.5 (2.3, 20.9) 28.1 ( 25.1 -28.4)
Tmax days 8 (5, 15) 4.0 (3.0-31.0)
Cmax ï­g/mL 2.13 (0.69, 5.80) 56.0 (21.2 -151)
CWk4 ï­g/mL 1.56 (0.63, 2.96) 34.6 (17.5 -69.3)
CWk8 ï­g/mL 0.91 (0.43, 1.57) 20.3 ( 10.4 -38.3)
CWk12 ï­g/mL 0.58 (0.18, 1.03) 13.5 (6.75 -25.6)
2018N357118_01 CONFIDE NTIA L
208832
29Parameter Units CAB RPV
Median (90% PI) Median (90% PI)
CWk24 ï­g/mL 0.18 (0.025, 0.45) 6.98 ( 3.33 -13.6)
CWk36 ï­g/mL 0.05 (0.025, 0.26) 4.88 ( 2.26 -9.68)
CWk48 ï­g/mL 0.025 (0.025, 0.16) 3.58 ( 1.66 -7.15)
CWk52 ï­g/mL 0.025 (0.025, 0.14) 3.24 ( 1.50 -6.49)
AUC 0-Wk4 ï­g*h/mL 1216 (422, 2857) 28354 (10674 -67476)
AUC 0-Wk8 ï­g*h/mL 2080 (811, 4132) 47419 (21949 -99140)
AUC 0-Wk12 ï­g*h/mL 2601 (1133, 4763) 58909 (29731 -116809)
AUC 0-Wk24 ï­g*h/mL 3271 (1788, 5461) 78560 (43502 -144786)
AUC 0-Wk36 ï­g*h/mL 3519 (2082, 5738) 91349 (51528 -164003)
AUC 0-Wk48 ï­g*h/mL 3634 (2215, 5852) 100079 (56879 -
178154)
AUC 0-Wk52 ï­g*h/mL 3655 (2240, 5868) 102380 (58332 -
182124)
4.3. End of Study  Definition
A participant is considered to have completed the study  if he/she has completed all 
phases of the stud y including the follow up visit Week 52.
The end of the stud y is defined as the date of the last visit of the last participant in the 
study .
5. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
Age
1. Participant must be 18 to 50years of age inclusive, at the time of signing the 
informed consent.
2018N357118_01 CONFIDE NTIA L
208832
30Type of Participant and Disease Characteristics
2.Participants who are overtly  health y as determined by medical evaluation including 
medical history , phy sical examination, laboratory  tests, and cardiac monitoring. 
3. A participant with a clinical abnormalit y or laboratory parameter(s) which is/are not
specificall y listed in the inclusion or exclusion criteria, outside the reference range
may be included onl y if the investigator in consultation with the Medical Monitor 
agree and document that the finding is unlikel y to introduce additional risk and will 
not interfere with the study procedures. A single repeat of a procedure or lab oratory
parameter is allowed to determine eligibility .
4.Participant s who are negative on two consecutive tests for SARS- CoV -2, performed 
at Screening and on Day  -1 of admission to the Phase I unit, using an approved 
molecular test (PCR or antigen test ).
Weight
5.Body weight â‰¥ 40 kg and body  mass index (BMI) within the range 18 to 35 kg/m2
(inclusive).
Sex
6.Male or female . Contraceptive use by  men or women should be consistent with local 
regulations regarding the methods of contraception for those participating in clinical 
studies.
a.Male Participants:
Male participants are eligible to participate if they  agree to the following during the 
intervention period and for at least 52 weeks after the last dose of study  intervention: 
ï‚·Refrain from donating sperm
Plus either:
ï‚·Be abstinent from heterosexual or homosexual intercourse as their preferred and 
usual lifesty le (abstinent on a long term and persistent basis) and agree to remain 
abstinent 
OR
ï‚·Must agree to use contraception/barrier as detailed below
oAgree to use a male condom (and should also be advised of the benefit 
for a female partner to use a highly  effective method of contraception 
as a condom may  break or leak) when having sexual intercourse with a 
woman of childbearing potential who is not currently  pregnant
oAgree to use male condom when engaging in an y activity  that allows 
for passage of ejaculate to another person
2018N357118_01 CONFIDE NTIA L
208832
31b.Female Participants: 
ï‚·A female participant is eligible to participate if she is not pregnant or breastfeeding, 
and at least one of the following conditions applies:
oIs not a woman of childbearing potential (WOCBP) 
OR
b.Is a WOCBP and using a contraceptive method that is highly  effective, with a failure 
rate of <1%, as described in Appendix 4 during the intervention period and fo r at 
least 52 weeks after the last dose of study  intervention. The investigator should 
evaluate the effectiveness of the contraceptive method in relationship to the first dose 
of study  intervention.
oA WOCBP must have a negative highly  sensitive ( Appendix 2 )pregnancy  test 
(urine or serum as required by  local regulations) within 30 day s ofthe first dose 
of study  intervention.
oIf a urine test cannot be confirme d as negative (e.g., an ambiguous result), a 
serum pregnancy  test is required. In such cases, the participant must be excluded 
from participation if the serum pregnancy  result is positive.
ï‚·Additional requirements for pregnancy  testing during and after study  intervention are 
located in Appendix 2 .
ï‚·The investigator is responsible for review of medical history , men strual history , and 
recent sexual activity  to decrease the risk for inclusion of a woman with an earl y 
undetected pregnancy
Informed Consent
7. Capable of giving signed informed consent as described in Appendix 1, which 
includes compliance with the requirements and restrictions listed in the I CF and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Signs and s ymptoms which in the opinion of the investigator are suggestive of 
COVID -19 (i.e. fever, cough etc) within 14 day s of inpatient admission
2.Contact with known COVID -19 positive person/s in the 14 day s prior to inpatient 
admission
3.History  or presence of/significant history of or current cardiovascular, respiratory , 
hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric 
disorders capable of significantly  altering the absorption, metabolism, or elimina tion 
of drugs; constituting a risk when taking the study intervention or interfering with the 
interpretation of data
2018N357118_01 CONFIDE NTIA L
208832
324.Abnormal blood pressure as determined b y the investigator.
5.Alanine transaminase (ALT) >1.5x upper limit of normal (ULN) .
6.Bilirubin >1.5xUL N(isolated bilirubin >1.5xULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%). 
7.Current or chronic history of liver disease, or known hepatic or biliary  abnormalities 
(with the exception of Gilbert's s yndrome or as ymptomatic gallstone s)
8.History  of ongoing or clinically  relevant seizure disorder within the previous 2 y ears, 
including participant s who have required treatment for seizures within this time 
period. A prior history  of seizure, with a seizure free period of at least 2 years, off 
anti-epileptics, may  be considered for enrolment if the investigator believes the risk 
of seizure recurrence is low. All cases of prior seizure history  should be discussed 
with the medical monitor prior to enrolment.
9.QTc >450 msec for male participan tsand >470 msec for female participan ts
NOTES:
ï‚·The QTc is the QT interval corrected for heart rate according to Bazettâ€™s 
formula (QTcB), Fridericiaâ€™s formula (QTcF), and/or another method, machine -
read or manuall y over -read.
ï‚·The specific formula that will be used to determine eligibility  and 
discontinuation for an individual participant should be determined prior to 
initiation of the study . In other words, several different formulae cannot be used 
to calculate the QTc for an individual participant and then the lowest QTc value 
used to include or discontinue the participant from the trial.
10.A participant , who has an underly ing skin disease or disorder (i.e. infection, 
inflammation, dermatitis, eczema, drug rash, drug allergy , psoriasis, food allergy , 
urticaria ). 
11.A participant , who is considered to have insufficient musculature to allow safe 
administration of CAB or RPV in the opinion of the investigator will be excluded.
Prior/Concomitant Therapy
12.Unable to refrain from the use of prescription or non-prescription drugs, including
vitamins, herbal and dietary  supplements (including St Johnâ€™s Wort) within 7 day s 
(or 14 day s if the drug is a potential enzy me inducer) or 5 half -lives (whichever is 
longer) prior to the first dose of study  medication tothecompletion of the follow -up 
visit unless in the opinion of the Investigator and ViiV Medical Monitor the 
medication will not interfere with the stud y procedures or compromise participant
safet y. The use of an y concurrent prohibited medications as outl ined in Section 6.4.2 .
Prior/Concurrent Clinical Study Experience
13. Participation in the study would result in loss of blood or blood products in excess of 
500 mL  withi n 56 day s. 
14. Exposure to more than four new chemical entities within 12 months prior to the first 
dosing day .
2018N357118_01 CONFIDE NTIA L
208832
3315. P articipant has participated in a clinical trial and has received an investigational 
product within the following time period prior to the first dosing day  in the current 
study : 30 day s, 5 half -lives or twice the duration of the biological effect of the 
investigation al product (whichever is longer).
Diagnostic assessments
16. Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months 
prior to first dose of study  intervention.
17.Positive Hepatitis C antibody  test result at screening or within 3 months pr ior to first 
dose of study  intervention.
NOTE:  Participants with positive Hepatitis C antibody  due to prior resolved disease can 
be enrolled, onl y if a confirmatory  negative Hepatitis C RNA test is obtained.
18.Positive Hepatitis C RNA test result at screeni ng or within 3 months prior to first 
dose of study  intervention.
NOTE: Test is optional and participant s with negative Hepatitis C antibody test are not 
required to also undergo Hepatitis C RNA testing.
19. P resence of the Hepatitis B core antibod y (HBcAb) sho uld also lead to exclusion 
from the study  even if HBsAg is negative.
Other Exclusions
20.Positive pre -study  drug/alcohol screen
21.Positive human immunodeficiency  virus (HIV) antibody  test
22. Regular use of known drugs of abuse
23.Regular alcohol consumption within 6 months prior to the study  defined as: 
ï‚·An average weekl y intake of >14 units for males or >7 units for females.  One 
unit is equivalent to 8 g of alcohol: a half -pint (~240 ml) of beer, 1 glass (125 
ml) of wine or 1 (25 ml) measure of spirits. 
24. Urinary  cotinine levels indicative of smoking or history  or regular use of tobacco- or 
nicotine -containing products (e.g. nicotine patches or vaporizing devices) within 6 
months prior to screening.
25. P articipant , who has a tattoo o r other dermatological condition overly ing the thigh 
region which may  interfere with interpretation of injection site reactions.
26.History  of sensitivity  to any  of the stud y medications, or components thereof or a 
history  of drug or other allergy  that, in th e opinion of the investigator or Medical 
Monitor, contraindicates their participation.
5.3. Lifest yle Considerations
5.3.1. Meals and Dietary  Restrictions
An overnight fast is preferred prior to screening laboratory  assessments; however, a 
minimum of a 6 hour fast is acceptable. Otherwise, food and drink can be given ad libitum 
2018N357118_01 CONFIDE NTIA L
208832
34throughout the course of the trial. At visits where participants will be in the clinic for 
multiple hours, meals will be provided by the study  site (in the form of a boxed lunch or 
card for use at the site cafeteria). 
Refrain from consumption of red wine, Seville oranges, grapefruit or grapefruit juice,
pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices during the oral lead in phase 
through Day  29 PK collection. 
5.3.2. Caffeine, A lcohol, and Tobacco
Participants will abstain from alcohol for 48 hours prior to initiating oral dosing and prior 
to the injection s. Participant s will abstain from alcohol for 48 hours prior to the collection 
of the pharmacokinetic sampling and clinical laboratory tests.
5.3.3. Activity
Participants will abstain from strenuous exercise for 48 hours before each blood 
collection for clinical laboratory  tests, and also the first 4 hours after injection. During 
this time, participants may participate in light recreational activities (e.g., watching 
television, reading).
5.4. Screen Failures
Screen failures are defined as participants who consent to participate inthe clinical study 
but are not subsequently  enrolled. A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure participants to meet the Consolidated 
Standards of Reporting Trials (CONSORT) publishing requir ements and to respond to 
queries from regulatory  authorities. Minimal information includes demography , screen 
failure details, eligibility criteria, any protocol deviations and any serious adverse events 
(SAEs).
Individuals who do not meet the criteria for participation in this study  (screen failure) ma y 
be rescreened. Rescreened p articipants should be assigned a new participant number.
6. STUDY INTERVENTION
Study  intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according 
to the study  protocol.
Investigational product (IP) in this protocol refers to the investigational study  drugs Oral 
CAB, CABLA, Oral RPV, and RPVLA. CAB and RPV products will be supplied by 
GlaxoSmithKline/ViiV Healthcare and Janssen Pharmaceuticals, respectively .
2018N357118_01 CONFIDE NTIA L
208832
35Dosing and Administration
CAB + RPV Oral Lead -InPhase
Day 1 to Day 
28Take one tablet of CAB 30 mg +  RPV 25 mg once daily with a meal
CAB LA + RPV LA Injection Phase
Injection Day 
1ï‚·Receive CAB LA 600 mg given as 1 X 3mLIM injection
ï‚·Receive RPV LA 900 mg given as 1 X 3mLIM injection 
6.1. Stud y Interventions A dministered
6.1.1. Formulations of CA B and RPV
6.1.1.1. Cabotegravir Tablets (CA B)
CAB is manufactured by GlaxoSmithKline and is formulated as white to almost white oval 
shaped film coated 30mgtablets for oral administration, packaged in high density 
polyethylene (HDPE) bottles with desiccant and child- resistant closure that include an 
induction seal. CAB tablets will be packaged in bottles of 30 tablets. Participants must keep 
all IP in its original pack container. GSK/ViiV will notify  sites if and when data are 
available to support the use of pill boxes. The recommended storage conditions, and expiry  
date w here required, are stated on the product label.
CAB Tablet is composed of cabotegravir sodium, lactose monohy drate, microcry stalline 
cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-
coating. The white film -coating contai ns hy promellose, titanium dioxide and polyeth ylene 
glycol.
6.1.1.2. Rilpivirine Tablets (RPV)
RPV is provided by Janssen Research & Development, LLC, a division of Janssen 
Pharmaceuticals, as 25mg tablets that are off-white, round, biconvex, film -coated and 
deboss ed on one side with â€œTMCâ€ and the other side with â€œ25â€. RPV is manufactured by 
Janssen- Cilag S.p.A, Latina, Italy. RPV will be provided as a globally  marketed product 
which includes approvals in the US and the European Union. RPV will be overlabeled and 
packaged in bottles of 30tablets. The recommended storage conditions, and expiry  date 
where required, are stated on the product label.
Each tablet contains 27.5 mg of rilpivirine hy drochloride, which is equivalent to 25 mg of 
RPV. Each tablet also contains the inactive ingredients croscarmellose sodium, lactose 
monohy drate, magnesium stearate, polysorbate 20, povidone K30 and silicified 
2018N357118_01 CONFIDE NTIA L
208832
36microcry stalline cellulose. The tablet coating contains hypromellose 2910 6 mPa.s, lactose 
monohy drate, PEG 3000, titanium dioxide and triacetin.
6.1.1.3. Cabotegravir Extended Release Suspension for Injection (CA B LA )
CAB LA (GSK1265744 LA) is manufactured by GlaxoSmithKline and is a sterile white to 
slightly  pink suspension containing 200mg/mL of GSK1265744 as free acid for 
administration by intramuscular (IM) injection. The product is packaged in a glass vial 
with a 13mm stopper and aluminum seal. Each vial is for single -dose use containing a 
withdrawable volume of 2.0mL (400mg) and does not require dilution prior to 
admi nistration. The recommended storage conditions, and expiry  date where required, are 
stated on the product label.
CAB LA is composed of cabotegravir free acid, polysorbate 20, polyeth ylene glycol 3350, 
mannitol, and water for injection.
6.1.1.4. Rilpivirine Extended Release Suspension for Injection (RPV LA ))
RPV LA (TMC278, GSK1329758, also named JNJ-16150108 -AAA), 300mg/mL 
Extended Release Suspension for Injection (G001), is provided by Janssen Research & 
Development, LLC, a division of Janssen Pharmaceuticals, as a sterile white suspension 
containing 300mg/mL of RPV as the free base. The route of administration is by 
intramuscular (IM) injection. RPV LA is packaged in a single use 4mL glass vial with a 
13mm stopper and aluminum seal. Each vial contains a nominal fill of 2.0mL (600mg) 
and does not require dilution prior to administration. The recommended storage conditions, 
and expiry  date where required, are stated on the product label.
RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate 
monohy drate, citric acid monohy drate, glucose monohy drate, sodium hydroxide, water for 
injection.
6.2. Preparation/Handling/Storage/A ccountability
The investigator or designee must confirm appropriate temperature conditions have been
maintained during transit for all study  intervention received and any discrepancies are 
reported and resolved before use of the stud y intervention.
Only  participants enrolled in the study  willreceive study  intervention and only  authorized 
site staff may supply or administer study intervention. All study  interventions must be 
stored in a secure, environmentally  controlled, and monitored (manual or automated) area 
in accordance with the labeled storage conditions with access limited to the investigator 
and authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study  intervention accountability , reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).
Further gu idance and information for the final disposition of unused study intervention are 
provided in the Study  Reference Manual ( SRM ). 
2018N357118_01 CONFIDE NTIA L
208832
37ï‚·Under normal conditions of handling and administration, study  intervention is not 
expected to pose significant safet y risks to site staff.  Take adequate precautions to 
avoid direct eye or skin contact and the generation of aerosols or mists. In the case of 
unintentional occupational exposure notify  the monitor, Medical Monitor and/or 
GSK/ViiV study  contact.
ï‚·Precaution will be taken to avoid direct contact with the study  intervention.  A M aterial 
Safety  Data Sheet (MSDS) describing occupational hazards and recommended 
handling precautions will be provided to the investigator. In the case of unintentional 
occupational exposure no tify the monitor, Medical Monitor and/or GSK/ViiV study  
contact.
6.2.1. Dosing Considerations for CA B LA  + RPV LA
Vials of CAB LA and RPV LA are each supplied as a suspension and need no further 
dilution or reconstitution. Since RPV LA requires refrigeration, sites should allow the 
vial(s) to come to approximately  room temperature prior to injecting. The vials should be 
gentl y inverted a few times to re-suspend sediments and allow bubbles to subside, and then 
use a syringe or provided vial adapter to withdraw the required volume of suspension for 
IM injection.
All injections must be given intramuscularl y in the thigh muscle, each injection on one 
thigh. The time and location of injection will be captured in the case report form ( CRF ).  
Additional injections instru ctions can be found in the SRM.
6.3. Stud y Intervention Compliance
ï‚·When participants are dosed at the site, they will receive study  intervention directly 
from the investigator or designee, under medical supervision.  The date and time of 
each dose administered in the clinic will be recorded in the source documents.  The 
dose of study intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering 
the study  intervent ion.  Study  site personnel will examine each participantâ€™s mouth to 
ensure that the stud y intervention was ingested.
ï‚·When participants self-administer study  intervention(s) at home, compliance with 
CAB + RPV dosing will be assessed through query ing the par ticipant during the site 
visits and documented in the source documents and CRF. IP accountability  will be 
evaluated using pill counts of unused I P (CAB and RPV tablets). 
ï‚·A record of the number of CAB + RPV tablets dispensed to and taken b y each 
participan t must be maintained and reconciled with study  intervention and 
compliance records. Intervention start and stop dates, including dates for intervention 
delay s and/or dose reductions will also be recorded in the CRF.
6.4. Concomitant Therapy
Any medication or vaccine (including over-the-counter or prescription medicines, 
vitamins, and/or herbal supplements or other specific categories of interest) that the 
2018N357118_01 CONFIDE NTIA L
208832
38participant is receiving at the time of enrollment or receives during the study  must be 
recorded along with:
ï‚·reason for use
ï‚·dates of administration including start and end dates
ï‚·dosage information including dose and frequency
The Medical Monitor should be contacted if there are any questions regarding concomitant 
or prior therap y.
6.4.1. Permitted Medications and Non -Drug Therapies
Participants must abstain from taking prescription drugs within 7 day s (or 14 day s if the 
drug is a potential enzy me inducer) or 5 half -lives (whichever is longer) before the start 
of study  intervention until completion of the follow -up visit , unless, in the opinion of the 
investigator and sponsor, the medication will not interfere with the study . 
Participants must abstain from taking non -prescription drugs (including vitamins and 
dietary  or herbal supplements) within 7 day s (or14 day s if th e drug is a potential enzy me 
inducer) or 5 half -lives (whichever is longer) before the start of study  intervention until
the last PK sample collected on Week 8, unless, in the opinion of the investigator and 
sponsor, the medication will not interfere with the study .
Paracetamol/Acetaminophen at doses of ï‚£2 grams/day  is permitted for use any time during 
the study . Other concomitant medication may  be considered on a case -by-case basis by  the 
investigator in consultation with the Medical Monitor if required.
Oral CAB and RPV only:
ï‚·Antacid products containing divalent cations (e.g., aluminum , calcium and magnesium) 
must be taken at least 2 hours before or at least 4 hours after oral CAB and RPV
ï‚·H2 antagonists must be taken at least 12 hours before or at least 4 hours after oral RPV 
oral RPV should not be co-administered with proton pump inhibitors, such as 
esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole
6.4.2. Prohibited Medications and Non- Drug Therapies
For participants receiving either formulation of CAB and RPV, the following 
medications could significantly  decrease the levels of CAB and/or RPV due to enzy me 
induction and therefore must not be administered concurrently :
ï‚·Carbamazepine
ï‚·Oxcarbazepine
ï‚·Phenobarbital 
ï‚·Pheny toin
ï‚·Rifabutin
ï‚·Rifampicin / rifampin, rifapentine
2018N357118_01 CONFIDE NTIA L
208832
39ï‚·Rifapentine
ï‚·St. Johnâ€™s wort ( Hypericum perforatum )
In addition, participant s must discontinue the following (or change to an allowable 
alternative) while receiving treatment with oral RPV:
ï‚·proton pump inhibitors, such as esomeprazole, lansoprazole, omeprazole, 
pantoprazole, rabeprazole;
ï‚·systemic dexamethasone (more than a single dose).
ï‚·anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phen ytoin.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances 
in which prohibited therapies are administered .
6.5. Dose Modification
No dose reductions, modifications, or changes in the frequency of an y components of each 
regimen will be allowed during the study  beyond what is allowed within the 
protocol. Protocol waivers or exemptions are not allowed. Therefore, adherence to the 
study  design requirements is essential and required for study  conduct. 
6.6. Intervention after the End of the Study
Participant s will not receive any additional treatment from GSK/ViiV Healthcare after 
completion of the study  because only healthy  participant s are eligible for study 
participation.
7. DISCONTINUA TION OF S TUDY INTERVENTION A ND 
PARTICIPA NT DISCONTI NUA TION/WITHDRA WAL
7.1. Discontinuation of Study  Intervention
Participants may volunta rily withdraw from the study  at any  time and for any  reason. Site 
investigators and stud y staff may withdraw participants before their scheduled termination 
visit for safet y, behavioral, or administrative reasons, or if the participants are unable or 
unwil ling to comply  with study  procedures. The reasons for withdrawals will be recorded 
in the participantsâ€™ study  records. If a participant withdraws from the study , he/she may 
request destruction of any samples taken, and the investigator must document this in the 
site study  records.
During the oral lead-in period, early withdrawal on medical grounds will occur if the 
participant develops a Grade 3 or higher AE that is judged b y the investigator to be related 
directly  to the study  product (see Appendix 3 and Appendix 4 ) for definitions and grading 
of sev erity of adverse events), or a  participant develops a  grade 3 or higher clinical 
significant laboratory  abnormality (see Division of AIDS [DAIDS ]table Appendix 7for 
grading) or any AE that is deemed clinically  significant by the i nvestigator and is judged 
by the investigator to be related directly  to the study  product.
For liver -related stopping criteria, please refer to Section 7.1.1 .
2018N357118_01 CONFIDE NTIA L
208832
40If a participant receives the injections, they will be followed 52-weeks post the final 
injection per protocol for appropriate procedures, including blood plasma PK sampling, 
and safet y evaluations, and will not be removed from the study for medical reasons, unless 
they refuse to continue participation.
During the oral lead in phase additional pre-specified reasons for discontinuing a 
participant from the study  (or, at minimum, discontin uing administration of study  product
and continuing safet y evaluations) include:
ï‚·Pregnancy  (please see Section 8.2.5)
ï‚·Protocol deviation
ï‚·Non-compliance
ï‚·Participant withdraws consent
ï‚·Participant lost to follow -up
ï‚·Investigator discretion
ï‚·Sponsor discontinues study
7.1.1. Liver Chemistry Stopping Criteria
Study  intervention will be discontinued for a participant if liver chemistry stopping 
criteria are met:
2018N357118_01 CONFIDE NTIA L
208832
41Phase I Liver Chemistry Stopping Criteria â€“Liver Stopping Event Algorithm
Abbreviations: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse 
event; ULN = upper limit of normal.
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf
Discontinuation of study treatment for abnormal liver tests should be considered by the 
investigator when a participant meets one of the conditions outlined or if the investigator 
believes that it is in the best interest of the participant.
Refer t o Appendix 6 for required Liver Safet y Actions and Follow up Assessments. 
7.1.2. QTc Stopping Criteria
A participant that meets the bulleted criterion be low will be withdrawn from the study .
ï‚·QTc > 500 msec
ï‚·QTc increase from baseline > 60 msec
ï‚·The same QT correction formula must be used for each individual participant to 
determine eligibility for and discontinuation from the study.  This formula may not be 
changed or substituted once the participant has been enrolled.
ï‚·For example, if a participant is eligible for the protocol based on QTcB, then 
QTcB must be used for discontinuation of this individual participant as well.
ï‚·Once the QT correction formula has been chosen for a participan tâ€™s eligibility , the 
same formula must continue to be used for that participant for all QTc data being 
collected for data anal ysis.  Safety  ECGs and other non -protocol specified ECGs 
are an exception.  

2018N357118_01 CONFIDE NTIA L
208832
42ï‚·The QTc should be based on the average of triplicate QTc values ECG readings
obtained over a brief (e.g., 5 -10 minute) recording period.  
7.2. Participant Discontinuation/Withdrawal from the Study
ï‚·A participant may  withdraw from the study  at any  time at his/her own request or may 
be withdrawn at any time at the discretion of the investigator for safet y, behavioral, 
compliance or administrative reasons. This is expected to be uncommon.
ï‚·At the time of discontinuing from the study , if possible, an early withdrawal visit 
should be conducted. See SoA for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be 
completed.
ï‚·The participant will be permanently  discontinued both from the study  intervention and 
from the study  at that time.
ï‚·If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any data collected before such a withdrawal of consent.
ï‚·If a participant withdraws from the study , he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site stud y 
records.
7.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
ï‚·The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study .
ï‚·Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 
telephone calls and, if necessary , a certified letter to the participantâ€™s last known 
mailing address or local equivalent methods). These contact attempts should be 
documented in the participantâ€™s medical record.
ï‚·Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study . 
Discontinuation of specific sites or of the study  as a whole are handled as part o f Appendix 
1.
2018N357118_01 CONFIDE NTIA L
208832
438. STUDY A SSESSMENTS A ND PROCEDURES
ï‚·Study  procedures and their timing are summarized in the SoA. 
If these assessments are scheduled for the same nominal time, THEN the assessments
should occur in the following order:
o12-lead ECG
ovital signs
oblood draws.
Note: The timing of the assessments should allow the blood draw to occur at the exact 
nominal time
ï‚·Protocol waivers or exemptions are not allowed 
ï‚·Safety  concerns should be discussed with the sponsor immediately  upon occurrence 
or awareness to determine if the participant should continue or discontinue study 
intervention.
ï‚·Adherence to the study  design requirements, including those specified in the SoA, is 
essential and required for study conduct.
ï‚·All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or recor d reasons 
for screening failure, as applicable. 
ï‚·Procedures conducted as part of the participantâ€™s routine clinical management (e.g., 
blood count) and obtained before signing of ICF may be utilized for screening or 
baseline purposes provided the procedure met the protocol -specified criteria and was 
performed within the time frame defined in the SoA.
ï‚·The maximum amount of blood collected from each participant over the duration 
of the study , including any extra assessments that may be required, will not excee d 
500 mL .
ï‚· Repeat or unscheduled samples may be taken for safet y reasons or for technical 
issues with the samples.
8.1. Safet y Assessments
Planned time points for all safety  assessments are provided in the SoA.
8.1.1. Physical Examinations
ï‚·A complete physical examination will include, at a minimum, assessments of the skin, 
cardiovascular, respiratory , gastrointestinal and neurological systems. Height and 
weight will also be measured and recorded.
ï‚·A brief physical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascular s ystem, and abdomen (liver and spleen).
2018N357118_01 CONFIDE NTIA L
208832
44ï‚·Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
8.1.2. Vital Signs
ï‚·Vital signs will be measured in a semi -supine position after 5 minutes rest and will 
include temperature, s ystolic and diastolic blood pressure, and pulse.
8.1.3. Electrocardiograms
ï‚·Triplicate 12-lead ECG will be obtained as outlined in the SoA (see Section 1.3) using 
an ECG machine that automatically  calculates the heart rate and measures P R, QRS, 
QT, and QTc intervals. Refer to Section 7for QTc withdraw al criteria and additional 
QTc readings that may  be necessary .
ï‚·At each time point at which triplicate ECGs are required, 3 individual ECG tracings 
should be obtained as closely  as possible in succession, but no more than 2 minutes 
apart. The full set of tr iplicates should be completed in less than 4 minutes. 12-lead 
ECGs will be performed with the subject in a supine position having rested in this 
position for at least 5 minutes beforehand.
8.1.4. Clinical Safety  Laboratory  Assessments
ï‚·Refer to Appendix 2 for the list of clinical laboratory  tests to be performed and to the 
SoA for the timing and frequency . 
ï‚·The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
signifi cant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  the investigator to be more severe than expected 
for the participant's condition.
ï‚·All laboratory  tests with values considered clinically  significantly  abnormal during 
participation in the study or within 7 days after the last dose of study  intervention 
should be repeated until the values return to normal or baseline or are no longer 
considered significantly  abnormal by  the investigator or medic al monitor. 
ï‚·If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology  should be identified ,and the sponsor 
notified.
ï‚·All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the SoA.
ï‚·Screening for SARS- CoV -2:Study  participants will be monitored at Screening 
and daily while inpatients for COVID -19 sy mptoms.  I nvestigator(s) should 
utilise the World Health Organisation (WHO)_Case Definitions to classify  
COVID -19 cases [ World Health Organisation , 2020].  While outpatients, 
participants should report to the unit any  symptoms suggestive of COVID -19.  
All participants who experience s ymptoms suggestive of COVID- 19 should be 
2018N357118_01 CONFIDE NTIA L
208832
45isolated in the unit o r at home and tested for SARS -CoV -2 using an approved 
molecular test (PCR or antigen test ).  If a participant tests positive or becomes 
symptomatic with suspected/confirmed COVID -19 while on-unit, then the 
remaining participants in that cohort on the unit should be discharged ).  The 
investigator should consider an y participant testing positive for SARS -CoV -2 
being discontinued from study  drug if COVID -19 sy mptoms are moderate to 
severe. Appropriate contact tracing for all participants testing positive will be 
performed within the unit.  This should be done in accordance with local 
legislation and guidelines. Appropriate follow up should be implemented for 
participants who discontinue the study  due to COVID -19.
8.1.5. Suicidal Ideation and Behavior Risk Monitoring
ï‚·Participant s willbe monitored appropriatel y and observed closel y for suicidal ideation 
and behavior or any other unusual changes in behavior. It is recommended that the 
investigator consider mental health consultation or referral for participants who 
expe rience signs of suicidal ideation or behavior. Participants presenting with new 
onset/treatment emergent depression should be advised to contact the investigator 
immediately  if symptoms of severe acute depression (including suicidal 
ideation/attempts) deve lop, because medical intervention and discontinuation of the 
study  medication may  be required.
8.2. Adverse Events and Serious A dverse Events
The definitions of an AE or SAE can be found in Appendix 3 .
AEs will be reported by the participant (or, when appropriate, by a  caregiver, 
surrogate, or the participant's legally  authorized representative).
The investigator and any qualified designees are responsible for detecting, 
documenting, and reporting events that meet the definition of an AE or SAE and 
remain responsible for following up AEs that are serious, considered related to the 
study  intervention or the study , or that caused the participant to discontinue the 
study  (see Section 7). 
8.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
ï‚·All SAEs will be collected from the start of intervention until the follow -up Week 
52 visit at the time points specified in the SoA (Section 1.3). However, an y SAEs 
assessed as related to study  participation (e.g., study  intervention, protocol -
mandated procedures, invasive tests, or change in existing therap y) or related to a 
GSK/ViiV product will be recorded from the time a participant consents to 
participate in the stud y.
ï‚·All AEs will be collected from the start of intervention until the follow -up Week 
52 visit  at the time points specified in the SoA (Section 1.3).
2018N357118_01 CONFIDE NTIA L
208832
46ï‚·Medical occurrences that begin before the start of study  intervention but after 
obtaining informed consent will be recorded on the Medical History /Current 
Medical Conditions section of the CRF not the AE section.
ï‚·All SAEs will be recorded and reported to the sponsor or designee immediately 
and under no circumstance should this exceed 24 hours, as indicated in Appendix 
3. The investigator will submit any updated SAE data to the s ponsor within 
24 hours of it being available.
ï‚·Investigators are not obligated to actively  seek AEs or SAEs after the conclusion 
of the study  participation. However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the 
study , and he/she considers the event to be reasonably  related to the study  
intervention or study  participation, the investigator must promptly  notify  the 
sponsor.
8.2.2. Method of Detecting AE s and SA Es
ï‚·The method of recording, evaluating, and assessing causality  of AEs and SAEs 
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 3 .
ï‚·Care will be taken not to introduce bias when detecting AE and/or SAE. Open -
ended and non-leading verbal questioning of the participant is the preferred 
method to inquire about AE occurrence. 
8.2.3. Follow -up of A Es and SA Es
ï‚·After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, will be followed until the event is 
resolved, stabilized, otherwise explained, or the participant is lost to follow -up (as 
defined in Section 7.3). Further information on follow -up procedures is given in 
Appendix 3 .
8.2.4. Regulatory  Reporting Requirements for SA Es
ï‚·Prompt notification by the investigator to the sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and the 
safet y of a stud y intervention under clinical investigation are met. 
ï‚·The sponsor has a legal responsibility  to notify both the local regulatory authority and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will compl y with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
ï‚·For all studies except those utilizing medical devices investigator safety  reports must 
be prepared for suspected unexpected serious adverse reactions (SUSAR) according 
to local regulatory  requirements and sponsor policy  and forwarded to investigators as 
necessary .
2018N357118_01 CONFIDE NTIA L
208832
47ï‚·An investigator who receives an investigator safety  report describing a SAE or other 
specific safet y information e.g., summary  or listing of SAEs) from the sponsor will 
review and then file it along with the Investigatorâ€™s Brochure and will notify  the 
IRB/IEC, i f appropriate according to local requirements.
8.2.5. Pregnancy
ï‚·Details of all pregnancies in female participants and female partners of male 
participants will be collected after the start of study  intervention and until 52-week
post injections. 
ï‚·If a pregnancy  is reported, the investigator should inform GSK/ViiV within 24 hours 
of learning of the pregnancy  and should follow the procedures outlined in Appendix 
4.
ï‚·Abno rmal pregnancy  outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
8.3. Treatment of Overdose
For the oral lead in p hase of this study , any dose of CAB > 30 mg and/or RPV > 25mg 
within a 24-hour time period will be considered an overdose. 
For the injection phase of the study , any dose of CAB LA > 600 mg and/or RPV L A > 
900 mg will be considered an overdose.
GSK/ViiV does not recommend specific treatment other than supportive care for an 
overdose.
The investigator will use clinical judgement to treat any  overdose.
In the event of an overdose, the investigator should:
1.Contact the Medical Monitor immediately .
2.Closely  monitor the participant for AE/SAE and laboratory  abnormalities until CAB 
and/or RPV can no longer be detected s ystemically . 
3.Document the quantit y of the excess dose as well as the duration of the overdosing in 
the CRF.
Decisions regarding dose interruptions or modifications will be made by  the investigator 
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant.
8.4. Pharmacokinetics
Blood samples of CAB (~ 2 mL each) and RPV (~2mL each) will be collected for 
measurement of plasma concentrations of CAB and RPV , respectivel y,as specified in the 
SoA.
ï‚·Samples may be collected at additional time points during the study  if warranted 
and agreed upon between the investigator and the sponsor. The timing of sampling 
may be altered during the course of the study  based on newl y available data (e.g., 
2018N357118_01 CONFIDE NTIA L
208832
48to obtain data closer to the time of peak plasma concentrations) to ensure 
appropriate monitoring.
ï‚·Instructions for the collection and handling of biological samples will be provided 
by the sponsor. The actual date and time (24 -hour clock time) of each sample wi ll 
be recorded.
ï‚·Samples will be used to evaluate the PK of CAB and RPV. Genetic analyses will 
not be performed on these plasma samples. 
Plasma anal ysis for CAB concentration determination will be performed under the control 
of GlaxoSmithKline, the details of which will be included in the Study Reference Manual 
(SRM) .Concentrations of CAB will be determined in plasma samples using the currently 
approved bioanaly tical methodology .Raw data will be archived at the bioanal ytical site 
(detailed in the SRM). 
Plasma RPV analy sis will be performed under the control of Janssen R&D. 
Concentrations of RPV will be determined in plasma samples using the currentl y 
approved bioanaly tical methodology .  Raw data will be archived at the bioanaly tical site. 
Permitted sampling window for the OLI Phase : 
Plasma PK Assessment Permitted Sampling Window
Day 1 (1 h) ï‚±15minï€ 
Day 1 (2 h) ï‚±15min ï€ 
Day 1 (3 h) ï‚±30 min ï€ 
Day 1 (4 h) ï‚±15min
Day 1 (6 h) ï‚±30 min
Day 1 (8 h) ï‚±1h
Day 1 (12 h) ï‚±1h
Day 2 (24 h) ï‚±2h
Day 14 ï‚±1 dayï€ 
Day 29 22-26h from Day  28 dose
Permitted sampling window for injection phase is provided in SoA. 
	
 	

	

CC*?* !
4
	!9;(			!
 
(	
		

		#		
	! 	:


:
((

		#	 			


		:
%			!9;	>!		
		#		 
		
	F		!	

:#	!		(	 	F	
	
		
		(		#	 :
9	
		!	
		 !#				

		!	$*:
C*@*  #.
	$	
				(		 #	:
!(	
	$*:
E*  #&:
&
	
$"
"
 		
	!"#*	# @A "*C(	
	
	!	3!	"B$):
3!	
"B$)		( 		#

		(J;A)	4:0#	 C:
#
#				"$'(		!:' 	
	CCI
2018N357118_01 CONFIDE NTIA L
208832
50time data, the following pharmacokinetic parameters will bedetermined, as data permit: 
AUC(0 -ï‚¥), AUC(0- t), Cmax, tmax, half -life ( tÂ½), and absorption rate co nstant (KA LA).
Plasma CAB and RPV concentration data will be presented in graphical and/or tabular 
form and will be descriptively  summarized. 
Details of PK anal yses will be provided in the report and anal ysis plan (RAP) separatel y. 
10. STATISTICA L CONSIDERA TIONS
10.1. Statistical Hy potheses
The primary  objective of this study  is to evaluate the pharmacokinetics of CAB and R PV 
following a single intramuscular administration of each in the lateral thigh of health y adult 
participant s. No formal statistical hypotheses are to be tested. Where appropriate, an 
estimation approach will be taken and point estimates and confidence intervals will be 
constructed. 
10.2. Sample Size Determination
There was no formal calculation of power or sample size for this study. Approximately  15
participants will receive CAB LA + RPV LA IM injections and provide informative safety 
and pharmacokinetic data based on feasibility considerations.
10.3. Populations for A nalyses
The following populations are defined:
Population Description
Enrolled All participants who sign the ICF.
Safety All participants who take at least 1 dose of study drug.
Pharmacokinetic
ConcentrationAll participants who undergo plasma PK sampling and have 
evaluable PK assay results. This population will be used for the 
concentration listing.
Pharmacokinetic 
ParameterAll participants who undergo plasma PK sampling and have 
evaluable PK parameters estimated. This population will be used 
for PK parameter listing, plotting of the concentration- time data 
and PK parameter summary.
10.4. Statistical A nalyses
The statistical analysis plan will be finalized prior to Database Release (DBR ) and it will 
include a more technical and detailed description of the statistical analy ses described in 
2018N357118_01 CONFIDE NTIA L
208832
51this section. This section is a summary  of the planned statistical analyses of the most 
important endpoints including primary  and key  secondary  endpoin ts.
10.4.1. General Considerations
Final analysis will be performed after the completion of the study  and final datasets 
authorization. Data will be listed and summarized according to GSK reporting standards, 
where applicable. 
Unless stated otherwise, descriptive summaries will include n, mean, standard deviation 
(SD), median, minimum, and maximum for continuous variables, whereas n and percent 
will be used as summary  statistics for categorical variables. For PK data, coefficient of 
variation (%CV), geometric mean with associated 95% confidence interval (CI), and the 
between -participant CV (%CVb) for the log-transformed PK parameters will also be 
provided as appropriate. 
Baseline or pre-dose assessment is the last available assessment prior to time of the first 
dose unless it is specified otherwise. If there are multiple assessments collected on the same 
scheduled time, the average of these assessments will be used. For tabulated safet y 
summaries, only  the scheduled assessments will be included in the summary  tables.
Version 9.4 or higher of the SAS system will be used to analyze the data as well as to 
generate tables, figures, and listings. Complete details will be documented in the RAP.
10.4.2. Primary  Endpoint (s)
Descriptive statistics and/or graphics will be created to describe the primary  endpoints of 
interest. Concentrations will be determined directly  from concentration -time data from 
each matrix.  Data will be presented in tabular and or graphical format and summarized 
descriptivel y according to GSKâ€™s I ntegrated Data Standards Library (IDSL) standards. No 
formal statistical testing will be conducted.
Pharmacokinetic analyses will be the responsibility  of Clinical Pharmacokinetics Modeling 
& Simulation Departm ent within GSK. Plasma CAB and RPV concentration -time data will 
be analyzed by non-compartmental methods with WinNonlin Professional 5.2 or higher, 
Phoenix (Pharsight Corporation) or comparable software. Calculations will be based on the 
actual sampling ti mes recorded during the study . 
The following pharmacokinetic parameters will be determined, as data permits, for the PK 
profile of CAB LA + RPV LA:
ï‚·maximum observed concentration (Cmax)
ï‚·time of maximum observed concentration (tmax) 
ï‚·area under the concen tration -time curve from time zero to last quantifiable time 
point (AUC(0- t)) 
ï‚·area under the concentration -time curve from time zero to infinity (AUC(0- ï‚¥))
ï‚·apparent terminal phase half -life (tÂ½) 
ï‚·absorption rate constant (KA LA)
2018N357118_01 CONFIDE NTIA L
208832
5210.4.3. Secondary  and Safety Endpoi nt(s)
All secondary  and safet y anal yses will be performed on the Safet y Population. AEs will be 
summarized using MedDRA preferred terms. All AEs, drug-related AEs, SAEs, liver-
related AEs and AEs leading to permanent discontinuation of study  drug or withdr awal 
will be summarized or listed. AEs and drug-related AEs will also be summarized by 
maximum toxicity  grade (based on DAIDScategories). Laboratory  data, vital signs and 
ECG data (absolute values and change from Baseline) will be summarized by visit. Liver 
chemistry  abnormalities will be summarized or listed.  Details will be documented in the 
RAP .
10.5. Interim Analyses
There is no planned formal interim analy sis.  All preliminary  safety, tolerability  and 
available pharmacokinetic data may  be reviewed internally  at anytime point.  Depending 
on feasibility , evaluation of PK data may  be performed at time points such as Wee k 4 and 
Week 12 post injection for preparatory  PK modelling.
2018N357118_01 CONFIDE NTIA L
208832
5311. SUPPORTING DOCUMENTA TION AND OPERA TIONAL
CONSIDERA TIONS
11.1. Appendix 1: Regulatory , Ethical, and Study  Oversight 
Considerations
11.1.1. Regulatory  and Ethical Considerations
ï‚·This study  will be conducted in accordance with the protocol and with:
ï‚·Consensus ofethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
ï‚·Appli cable ICH Good Clinical Practice (GCP) Guidelines
ï‚·Applicable laws and regulations
ï‚·The protocol, protocol amendments, ICF, Investigator Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by 
the investigator and reviewed and approved by the IRB/IEC before the study  is 
initiated. 
ï‚·Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
ï‚·The investigator will be responsible for the following:
ï‚·Providing written summaries of the status of the study  to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  the IRB/E C
ï‚·Notify ing the IRB/IEC of SAE or other significant safety  findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the study  at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies 
(if applicable), and all other applicable local regulations.
11.1.2. Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y ear after comple tion of the study .
11.1.3. Informed Consent Process
ï‚·The investigator or his/her representative will explain the nature of the study  to the 
participant and answer all questions regarding the study . 
2018N357118_01 CONFIDE NTIA L
208832
54ï‚·Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guideline s, 
Health Insurance Portability  and Accountability  Act (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center. 
ï‚·The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF.
ï‚·Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study . 
ï‚·A copy of the ICF(s) must be provided to the participant or the participantâ€™s legally 
authorized representative. 
Participants who are rescreened are required to sign a new ICF.
GSK/ViiV (alone or working with others) may use participantâ€™s coded study  data and 
samples and other information to carry  out this study ; understand the results of this study ; 
learn more about the study  intervention and the injection site; publish the results of these 
research efforts; work with government agencies or insurers to have th e study intervention 
approved for medical use or approved for pay ment coverage. 
11.1.4. Data Protection
ï‚·Participants will be assigned a unique identifier by the sponsor. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any information which would make the participant identifiable 
will not be transferred. 
ï‚·The participant must be informed that his/her personal study- related data will be used 
by the sponsor in accordance with local data protection law. The level of disclosure 
must also be explained to the participant who will be required to give consent for their 
data to be used as described in the informed consent. 
ï‚·The participant must be informed that his/her medical records may be exami ned by 
Clinical Quality  Assurance auditors or other authorized personnel appointed by the 
sponsor, by appropriate IRB/IEC members, and by inspectors from regulatory 
authorities.
11.1.5. Dissemination of Clinical Study  Data
ï‚·Where required by applicable regulatory  requirements, an investigator signatory  will 
be identified for the approval of the clinical study  report.  The investigator will be 
provided reasonable access to statistical tables, figures, and relevant reports and will 
have the opportunity  to review the complete stud y results at a GSK/ViiV site or other 
mutually -agreeable location.
ï‚·GSK/ViiV will also provide the investigator with the full summary  of the study  results.  
The investigator is encouraged to share the summary  results with the study 
participants, as appropriate.
2018N357118_01 CONFIDE NTIA L
208832
55ï‚·The procedures and timing for public disclosure of the protocol and results summary  
and for development of a manuscript for publication for this study  will be in 
accordance with GSK Policy .
ï‚·GSK /ViiV intends to make anon ymized participant- level data from this trial available 
to external researchers for scientific analyses or to conduct further research that can 
help advance medical science or improve patient care. This helps ensure the data 
provided by trial participants are used to maximum effect in the creation of knowledge 
and understanding
11.1.6. Data Quality  Assurance
ï‚·All participant data relating to the stud y will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (e.g., laboratory data). The
investigator is responsible for verify ing that data entries are accurate and correct by 
physicall y or electronically  signing the CRF. 
ï‚·The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
ï‚·The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
ï‚·Monitoring details describing strategy  (e.g., risk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Anal ytical Risk-
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on-site 
monitoring) are provided in the Monitoring Plan.
ï‚·The sponsor or designee is responsible for the data management of this study including 
quality  checking of the data. 
ï‚·The sponsor assumes accountability  for actions delegated to other individuals (e.g., 
Contract Research Organiz ations).
ï‚·Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other study  agreements, ICH GCP, and all applicable 
regulatory  requirements. 
ï‚·Records and documents, including signed ICF, pertaining to the conduct of this study 
must be retained by the investigator for 15 years from the issue of the final Clinical 
Study  Report (CSR)/ equivalent summary unless local regulations or institutional 
policies require a longer retention period. No records may be destro yed during the
retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. 
2018N357118_01 CONFIDE NTIA L
208832
5611.1.7. Source Documents
ï‚·Source documents provide evidence for the existence of the participant and 
substantiate the integrit y of the data collected. Source documents are filed at the 
investigatorâ€™s site.
ï‚·Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the disc repancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
ï‚·Definition of what constitutes source data can be found in Monitoring P lan. 
11.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the first site open and will be the study  start date.
GSK/ ViiV or its designee reserves the right to close the stud y site or terminate the stud y at 
any time for any reason at the sole discretion of GSK//ViiV . Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site by the sponsor or investigator may include but 
are not limited to:
ï‚·Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP gui delines
ï‚·Inadequate recruitment of participants by  the investigator
ï‚·Discontinuation of further study  intervention development
If the study is prematurely terminated or suspended, the sponsor shall promptly  inform the 
Investigators, the IECs/IRBs, the regula tory authorities, and any contract research 
organization(s) used in the study  of the reason for termination or suspension, as specified 
by the applicable regulatory  requirements. The Investigator shall promptly  inform the 
participant and should assure appr opriate participant therap y and/or follow-up, if required.
11.1.9. Publication Policy
ï‚·The results of this study  may  be published or presented at scientific meetings. If this 
is foreseen, the investigator agrees to submit all manuscripts or abstracts to the 
sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
2018N357118_01 CONFIDE NTIA L
208832
57ï‚·The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publication of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordinating investigator will be designated b y mutual 
agreement.
ï‚·Authorship will be determined by mutual agreement and in line with I nternational 
Committee of Medical Journal Editors authorship requirements.
2018N357118_01 CONFIDE NTIA L
208832
5811.2. Appendix 2: Clinical Laboratory  Tests
ï‚·The tests detailed in Table 3will be performed b y the local laboratory . 
ï‚·Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5of the protocol.
ï‚·Additional tests may  be performed at an y time during the stud y as determined 
necessary  by the investigator or required by  local regulations.
ï‚·Pregnancy  Testing 
ï‚·Refer to Section 5.1Inclusion Criteria for screening pregnancy  criteria.
ï‚·Pregnancy  testing (urine or serum as required by  local regulations) should be 
conducted per SoA.
ï‚·Additional serum or urine pregnancy  tests may  be performed, as determined 
necessary  by the investigator or required by  local regulation, to establish the 
absence of pregnancy  at any  time during the participant's participation in the 
study .
Table 3 Protocol -Required Safety  Laboratory  Assessments
Laboratory 
Assessments1Parameters
Hematology Platelet Count RBC Indices:
Mean Corpuscular 
Volume
Mean Corpuscular 
Hemoglobin
%ReticulocytesWhite Blood Cellcount 
with Differential :
Neutrophils
Lymphocytes
Monocytes
Eosinophils
BasophilsRed blood cell ( RBC )
Count
Hemoglobin
Hematocrit
Clinical 
Chemistry2Blood Urea 
NitrogenPotassium Aspartate 
Aminotransferase
(AST)/ Serum 
Glutamic-
Oxaloacetic 
Transaminase
(SGOT)Total and direct 
bilirubin
Creatinine Sodium Alanine 
Aminotransferase
(ALT)/ Serum 
Glutamic- Pyruvic 
Transaminase
(SGPT)Total Protein
Glucose fasting Calcium Alkaline 
phosphatase
Coagulation 
testsProthrombin Time Partial Thromboplastin 
TimeInternational 
Normalized Ratio
2018N357118_01 CONFIDE NTIA L
208832
59Laboratory 
Assessments1Parameters
Routine 
Urinalysisï‚·Specific gravity
ï‚·pH, glucose, protein, blood, ketones by dipstick
ï‚·Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
Testsï‚·HIV: HIV 1 -2 antibody/antigen ( Ab/Ag )testing
ï‚·Hepatitis B screen: Hepatits B surface antigen (HBsAg) 
ï‚·Hepatitis B surface antibody(HBsAb), and Hepatitis core antibody 
(HBcAb)
ï‚·Hepatitis C (Hep C antibody)
ï‚·Alcohol screen and drugs of abuse screen (to include at minimum: 
amphetamines, barbiturates, cocai ne, opiates, cannabinoids and 
benzodiazepines)
ï‚·Urine (or serum) human Chorionic Gonadotropin Pregnancy test (as 
needed for women of child bearing potential)4
The results of each test must be entered into the CRF.
NOTES:
1. An overnight fast is preferred prior to screening laboratory assessments; however, a minimum of a 6 hour fast 
is acceptable.  
2. Details of liver chemistry stopping criteria and required actions and follow -up assessments after liver stopping 
or monitoring ev ent are given in Section 7.1and Appendix 7 All events of ALT ï‚³ 3 Ã— upper limit of normal (ULN) 
and bilirubin ï‚³2 Ã— ULN (>35% direct bilirubin) or ALT ï‚³3 Ã— ULN and international normalized ratio (INR) >1.5, if 
INR measured, which may indicate severe liver injury (possible Hyâ€™s Law), must be reported as an SAE 
(excluding studies of hepatic impairment or cirrhosis).
3. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or 
IRB/IEC.
2018N357118_01 CONFIDE NTIA L
208832
6011.3. Appendix 3: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
11.3.1. Definition of A E
AE Definition
ï‚·An AE is an y untoward medical occurrence in a clinical study participant, 
temporally  associated with the use of a study  intervention, whether or not 
considered related to the study  intervention.
ï‚·NOTE: An AE can therefore be an y unfavorable and unintended sign (including 
an abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally  associated with the use of a study  intervention.
Events Meeting the AE Definition
ï‚·Any abnormal laborato ry test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientifi c judgment of the investigator (i.e., not 
related to progression of underly ing disease).
Note: Clinically  significant laboratory  abnormalities captured as AEs should be graded 
as per the clinical AE grade criteria, rather than by laboratory  grade to be graded by  the 
central laboratory  or central statistical anal ysis group using DAIDS laboratory grading 
criteria as per 
ï‚·Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
ï‚·New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
ï‚·Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
ï‚·Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
ï‚·The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will 
be reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, 
"lack of efficacy " or "failure of expected pharmacological action" constitutes an 
AE or SAE.
2018N357118_01 CONFIDE NTIA L
208832
61Events NOT Meeting the AE Definition 
ï‚·Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  
the investigator to be more severe than expected for the participantâ€™s condition.
ï‚·The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participantâ€™s condition.
ï‚·Medical or surgical procedure (e.g., endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
ï‚·Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
ï‚·Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
11.3.2. Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/sy mptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
oResults in death
oIs life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
Requires inpatient hospitalization or prolongation of existing hospitalization
ï‚·In general, hospitalization signifies that the participant has been detained 
(usually  involving at least an overnight stay ) at the hospital or emergency  ward 
for observation and/or treatment that would not have been appropriate in the 
physicianâ€™s office or outpatient setting. Complications that occur during 
hospitalization are AE. If a complication prolongs hospitalization or fulfills any  
other serious criteria, the event is serious. When in doubt as to whether 
â€œhospitalizationâ€ occurred or was necessary , the AE should be considered 
serious.
ï‚·Hospitalization for elective treatment of a pre- existing condition that did not 
worsen from baseline is not considered an AE.
2018N357118_01 CONFIDE NTIA L
208832
62Results in persistent or significant disability/ incapacity
ï‚·The term disability means a substantial disruption of a personâ€™s ability  to conduct 
normal life functions.
ï‚·This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vo miting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:
ï‚·Medical or scienti fic judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
ï‚·Examples of such events include invasive or malignant cancers, intensive 
treatment in an em ergency  room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
Is associated with liver injury  and impaired liver function defined as: 
ï‚·ALT â‰¥ 3xULN and total bilirubin* â‰¥ 2xUL N (>35% direct), or 
ï‚·ALT â‰¥ 3xULN and INR** > 1.5. 
* Serum bilirubin fractionation should be performed if testing is available; if 
unavailable, measure urinary  bilirubin via dipstick.  If fractionation is unavailable and 
ALT â‰¥ 3xULN and total bilirubin  â‰¥ 2xUL N, then the event is still to be reported as an 
SAE. 
** INR testing not required per protocol and the threshold value does not apply  to 
participants receiving anticoagulants.  If INR measurement is obtained, the value is to 
be recorded on the SAE form.
11.3.3. Recording and Follow -Up of A E and S AE
AE and SAE Recording
ï‚·When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e.g. hospital progress notes, laboratory , and diagnostics reports) 
related to the event.
ï‚·The investigator will then record all relevant AE/SAE information in the CRF.
2018N357118_01 CONFIDE NTIA L
208832
63ï‚·It is notacceptable for the investigator to send photocopies of the participantâ€™s 
medical records to GSK in lieu of completion of the GSK /AE/SAE CRF page.
ï‚·There may  be instances when copies of medical records for certain cases are 
requested b y GSK. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK.
ï‚·The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE/SAE.
Asses sment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y  and assign it to 1 of the following categories per Appendix 7 : 
ï‚·Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
ï‚·Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
ï‚·Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AE and SAE can be assessed as severe.
An event is defined as â€˜ seriousâ€™ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
ï‚·The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
ï‚·A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
ï‚·The investigator will use clinical judgment t o determine the relationship.
ï‚·Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
ï‚·The investigator will also consult the Investigatorâ€™s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
ï‚·For each AE/SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE/SAE and has provide d an assessment of causality .
ï‚·There may  be situations in which an SAE has occurred, and the investigator has 
minimal information to include in the initial report to GSK. However, it is very 
2018N357118_01 CONFIDE NTIA L
208832
64important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK .
ï‚·The investigator may  change his/her opinion of causality  in light of follow -up 
information and send an SAE follow- up report with the updated causality  
assessment.
ï‚·The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
ï‚·The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  GSK 
to elucidate the nature and/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
ï‚·If a participant dies during participation in the study or during a recognized 
follow -up period, the investigator will provide GSK with a cop y of an y post -
mortem findings including histopatho logy.
ï‚·New or updated information will be recorded in the originally  completed CRF.
ï‚·The investigator will submit any  updated SAE data to GSK within 24 hours of 
receipt of the information.
11.3.4. Reporting of SA E to GSK
SAE Reporting to GSK/ViiV via Electronic Data Collection Tool
ï‚·The primary  mechanism for reporting SAE to GSK will be the electronic data 
collection tool.
ï‚·If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
ï‚·The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
ï‚·The investigator or medically -qualified sub -investigator must show evidence 
within the eCRF (e.g., check review box, signature, etc.) of rev iew and verification 
of the relationship of each SAE to I P/study  participation (causalit y) within 72 
hours of SAE entry  into the eCRF.
ï‚·After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the e ntry of new data or changes to existing data.
ï‚·If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection tool 
has been taken off -line, then the site can repor t this information on a paper SAE 
form (see next section) or to the medical monitor/SAE coordinator b y telephone.
2018N357118_01 CONFIDE NTIA L
208832
65ï‚·Contacts for SAE reporting can be found in SRM.
SAE Reporting to GSK/ViiV via Paper CRF
ï‚·Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the medical monitor or the SAE coordinator.
ï‚·In rare circumstances and in the absence of facsimile equipment, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by 
overni ght mail or courier service.
ï‚·Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time 
frames.
ï‚·Contacts for SAE reporting can be found in SRM.
2018N357118_01 CONFIDE NTIA L
208832
6611.4. Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy  Information
11.4.1. Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
If fertility  isunclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cy cle 
cannot be confirmed before first dose of stud y intervention, additional evaluation should 
be considered.
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
ï‚·Documented h ysterectomy
ï‚·Documented bilateral salpingectomy
ï‚·Documented bilateral oophorectom y
For individuals with permanent infertility  due to an alternate medical cause other 
than the above, (e.g., mullerian agenesis, androgen insensitivity ), investigator 
discretion should be applied to determining stud y entry .
Note: Documentation can come from the site personnelâ€™s: review of the 
participantâ€™s medical records, medical examination, or medical history  interview.
3.Postmenopausal female
ï‚·A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 
ï‚·A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women no t 
using hormonal contraception or hormonal replacement therap y (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required. 
ï‚·Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -estrogen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before 
study  enrollment.
2018N357118_01 CONFIDE NTIA L
208832
6711.4.2. Contraception G uidance:
ï‚· CONTRACEPTIVESaALLOWED DURING THE STUDY INCLUDE:
ï‚· Highly Effective MethodsbThat Have Low User Dependency Failure rate of <1% per 
year when used consistently and correctly.
ï‚· Implantable progestogen -only hormone contraception associated with inhibition of 
ovulationc
ï‚· Intrauterine device (IUD)
ï‚· Intrauterine hormone -releasing system (IUS)c
ï‚· Bilateral tubal occlusion
ï‚· Vasectomized partner
ï‚· Note: Vasectomized partner is a highly effective contraceptive method provided that 
the partner is the sole s exual partner of the woman of childbearing potential and the 
absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. Spermatogenesis cycle is approximately 90 days.
ï‚· Highly Effective MethodsbThat Are User Dependent Failure rate of <1%  per year when 
used consistently and correctly.
ï‚· Combined (estrogen -and progestogen -containing) hormonal contraception associated with 
inhibition of ovulationc
ï‚· oral
ï‚· intravaginal
ï‚· transdermal
ï‚· injectable
ï‚· Progestogen -only hormone contraception associated with inhibition of ovulationc
ï‚· oral
ï‚· injectable
ï‚· Sexual abstinence
ï‚· Note: Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with 
the study intervention. The reliability of sexual abstinence needs to be evaluated in 
relation to the duration of the study and the preferred and usual lifestyle of the 
participant.
a. Contraceptive use by men or women should be consistent with local regulations regarding the use of 
contraceptive methods for those participating in clinical studies.
b. Failure rate of <1%  per year when used consistently and correctly. Typical use failure rates differ from those 
when used consistent ly and correctly.
c. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable 
contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.
Note: Periodic abstinence (calendar , sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Male 
condom and female condom should not be used together (due to risk of fa ilure with friction)
2018N357118_01 CONFIDE NTIA L
208832
6811.4.3. Collection of Pregnancy  Information:
Male participants with partners who become pregnant
ï‚·Investigator will attempt to collect pregnancy  information on any  male participantâ€™s 
female partner who becomes pregnant while participating in t his study . This applies 
only to male participants who receive CAB + RPV.
ï‚·After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the 
appropriate form and submit it to GSK within 24 hours of learning of the partnerâ€™s 
pregnancy . 
ï‚·The female partner will also be followed to determine the outcome of the pregnancy . 
Information on the status of the mother and child will be forwarded to GSK.
ï‚·Generally , follow -up will be no longer than 6 to 8 weeks following the estimated 
delivery  date. An y termination of the pregnancy  will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure. 
Female Participants who become pregnant
ï‚·Investi gator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
ï‚·The initial information will be recorded on the appropriate form and submitted to 
GSK within 24 hours of learning of a participant's pregnancy . 
ï‚·Participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK Generall y, follow- up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.  
ï‚·Any termination of pregnancy  will be reported, regardless of fetal status ( presence or 
absence of anomalies) or indication for procedure. 
ï‚·While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
ï‚·A spontane ous abortion (occurring at < 22 weeks gestational age) or still birth 
(occurring at > 22 weeks gestational age) is always considered to be an SAE and will 
be reported as such. 
ï‚·Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  intervention b y the investigator, will be reported to 
GSK as described in Appendix 3 . While the investigator is not obligated to activel y 
seek thi s information in former stud y participants, he or she may learn of an SAE 
through spontaneous reporting. 
Any female participant who becomes pregnant in OLI phase. will discontinue study  
intervention if participant gets pregnant and will not receive IM injections. 
If participant gets pregnant after receiving CAB LA and RPV L A, the participant should 
be followed up through 52 weeks post injections. 
2018N357118_01 CONFIDE NTIA L
208832
6911.5. Appendix 5: Genetics
USE/ANALYSIS OF DNA
ï‚·Genetic variation may  impact a particip antâ€™s response to study intervention, 
susceptibility , severit y and progression of disease. Variable response to study 
intervention may  be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology ; and/or molecular subty pe of the disease being treated. Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis
ï‚·DNA samples will be used for research related to CAB and/or RPV. T hey may  also 
be used to develop tests/assay s including diagnostic tests related to CAB and/or RPV 
and other medicines used to treat or prevent HIV infection. Genetic research may  
consist of the anal ysis of one or more candidate genes or the analy sis of gen etic 
markers throughout the genome (as appropriate)
ï‚·Additional analy ses of DNA samples may  be conducted if it is hy pothesized that this 
may help further understand the clinical data. 
ï‚·The samples may  be analy zed as part of a multi- study  assessment of genet ic factors 
involved in the response to CAB and/or RPV or study  interventions of this class. The 
results of genetic anal yses may  be reported in the clinical study  report or in a 
separate study  summary .
ï‚·The sponsor will store the DNA samples in a secure stor age space with adequate 
measures to protect confidentiality . 
ï‚·The samples will be retained while research on CAB and/or RPV (or study 
interventions of this class) or and other medicines used to treat or prevent HIV 
infection continues but no longer than 15 years after the last participant last visit or 
other period as per local requirements.
2018N357118_01 CONFIDE NTIA L
208832
7011.6. Appendix 6: Liver Safety : Required A ctions and Follow -up 
Assessments 
Phase 1 l iver chemistry  stopping criteria have been designed to assure participant safet y 
and to evaluate liver event etiology  
Phase 1 liver chemistry stopping criteria and required follow up assessments
Liver Chemistry Stopping Criteria 
ALT- absoluteALTâ‰¥3xULN
If ALT â‰¥3xULN AND bilirubin1,2ï‚³2xULN (>35% direct bilirubin) or 
international normalized ratio (INR) >1.5, Report as an SAE.
See additional Actions and Follow Up Assessments listed below
Required Actions and Follow up Assessments 
Actions Follow Up Assessments
ï‚·Immediately discontinue study intervention
ï‚·Report the event to GSK within 24 hours
ï‚·Complete the liver event CRF, and 
complete an SAE data collection tool if the 
event also meets the criteria for an SAE2
ï‚·Perform liver event follow up assessments 
ï‚·Monitor the participant until liver 
chemistries resolve, stabilize , or return to 
within baseline (see MONITORING below)
MONITORING:
If ALT â‰¥3xULN AND bilirubin ï‚³2xULN or INR 
>1.5
ï‚·Repeat liver chemistries (include ALT, 
aspartate transaminase [AST ], alkaline
phosphatase, bilirubin and INR) and 
perform liver event follow up assessments 
within 24 hours
ï‚·Monitor participant twice weekly until liver 
chemistries resolve, stabilise or return to 
within baseline
ï‚·A specialist or hepatology consultation is 
recommendedï‚·Viral hepatitis serology3
ï‚·Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend
ï‚·Obtain blood sample for pharmacokinetic 
(PK) analysis, obtained CAB + RPV of 
last dose4 
ï‚·Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
ï‚·Fractionate bilirubin, if total 
bilirubin ï‚³2xULN
ï‚·Obtain complete blood count with 
differential to assess eosinophilia
ï‚·Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
ï‚·Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications.
ï‚·Record alcohol use on the liver event 
alcohol intake CRF
2018N357118_01 CONFIDE NTIA L
208832
71Liver Chemistry Stopping Criteria 
If ALT â‰¥3xULN AND bilirubin < 2xULN and 
INR â‰¤1.5:
ï‚·Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin and INR) 
and perform liver event follow up 
assessments within 24-72 hours
ï‚·Monitor participant weekly until liver 
chemistries resolv e, stabilize or return to 
within baselineIf ALT â‰¥3xULN AND bilirubin ï‚³2xULN or 
INR >1.5 :
ï‚·Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti- liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or g amma 
globulins.
ï‚·Serum acetaminophen adduct high 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver injury 
in participants with definite or likely 
acetaminophen use in the preceding 
week) [ James, 2009]. NOTE: not 
required in China .
ï‚·Liver imaging (ultrasound, magnetic 
resonance, or computerized tomography) 
and /or liver biopsy to evaluate liver 
disease; complet e Liver Imaging and/or 
Liver Biopsy CRF forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study intervention for that participant if ALT ï‚³3xULN and bilirubin ï‚³2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on 
dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2. All events of ALT ï‚³3xULN and bilirubin ï‚³ 2xULN (>35% direct bilirubin) or ALT ï‚³3xULN and INR>1.5, which 
may indicate severe liver injury (possible â€˜Hyâ€™s Lawâ€™), must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis); the INR threshold value stated will not apply to participants receiving anticoagulants
3. Includes: Hepatitis A immunoglobulin ( IgM) antibody; HBsAg and HBcAb; Hepatitis C RNA; Cytomegalovirus IgM 
antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile an tibody or 
monospot testing) and Hepatitis E IgM antibody 
4. PK sample may not be required for participants known to be receiving placebo or non -GSK comparator 
interventions.  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
intervention prior to PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participantâ€™s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in t he time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shipping are in the SRM . 
References
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA,et al. 
Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen Overdose 
and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.
2018N357118_01 CONFIDE NTIA L
208832
7211.7. Appendix 7: Division of A IDS Table for Grading the Severity  
of Adult and Pediatric A dverse Events Version 2.1, March 
2017
The Division of AIDS Table for Grading the Severity  of Adult and Pediatric Adverse 
Events (â€œDAIDS AE Grading Tableâ€) is a descriptive terminology  which can be utilized
for Adverse Event (AE) reporting.  A grading (severity) scale is provided for each AE 
term. 
The table can be found at: 
Divis ion of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events (Corrected Version 2.1 - July 2017)
Reference
U.S. Department of Health and Human Services, National Institutes of Health, National 
Institute of Allergy  and Infectious Diseases, Division of AIDS. Division of AIDS 
(DAIDS) Table for Grading the Severity  of Adult and Pediatric Adverse Events, Version 
2.1. [March 2017]. Available from:
https://rsc.tech- res.com/docs/default -source/safet y/daids -ae-grading -table -mar2017.pdf
2018N357118_01 CONFIDE NTIA L
208832
7311.8. Appendix 8: Permissible Procedures during the COVID -19 
Pandemic
The COVID -19 pandemic presents significant logistical challenges for many  clinical sites 
around the world, with variable restrictions being placed on site resources and operations, 
and on an individual participant â€™s ability  to attend clinic visits.  Based on these 
challenges, it may  be necessary  to adopt additional measures and procedures to protect 
participant safety , and to allow flexibility  to allow conduct of the study . 
Permissible changes to procedures during the COVID -19 pandemic if deemed necessary  
by the investigator are outlined below. The investigator should discuss with the medical 
monitor the rationale if any  of these changes are required for a participant. For further 
details refer to the Study  Reference Manual (SRM).
ï‚·Participants previously  deemed eligible during the screening period unable to attend 
within the allowable screening window due to COVID -19 may  be rescreened. 
ï‚·Oral CAB dosing Day s 1 to 28. All doses except Day  1 and Da y 14 may be 
administered at home if participants are unable to attend due to COVID -19.  
ï‚·AE assessments during the oral lead in may  be conducted by  telephone at home if 
participants are unable to attend due to COVID -19.  
ï‚·Duration of admission to the clini c may  be extended if deemed necessary  by the 
investigator due to the COVID -19 pandemic.
ï‚·The 10to 14 -day washout period after the oral lead in may  be extended if deemed 
necessary  by the investigator due to the COVID- 19 pandemic.
ï‚·If a participant has suspec ted COVID -19, or tests positive for COVID -19, or has 
potential COVID19 exposure while enrolled in the study , the Investigator must assess 
the impact of this disease/situation on the benefit/risk for the participant(s) to 
continue in the study , as well as i f the participant has met protocol withdrawal 
criteria. Any adverse e vents related to the COVID -19 infection should continue to be 
evaluated as to whether they meet SAE criteria as defined in Section 11.3.2 ., and if 
so, reported in line with the SAE reporting requirements (Section 11.3.4 ). 
Investigator(s) should utilise WHO Case Definitions to classify  COVID -19 cases 
[World Health Organisation , 2020].  The Sponsor recognises that COVID- 19 case 
definitions may  evolve during the study  period, the most recent edition should be 
consulted for each case.  For all AEs or SAEs related to COVID -19, details should 
also be entered into the specific COVID -19 eCRF.  The study  site should contact the 
study  Medical Monitor for questions related to definitions and reporting, an d 
decisions around impact to study  drug continuation in the setting of clinically  defined 
mild COVI D-19 infection.
2018N357118_01 CONFIDE NTIA L
208832
7411.9. Appendix 9: Abbreviations and Trademarks
AC Active control
AE Adverse Event
ALT Alanine aminotransferase (SGPT)
AST Aspartate aminotransferase (SGOT)
AUC Area under concentration- time curve
AUC(0 -ï´) Area under the concentration- time curve over one dosing 
interval
AUC(0 -24) Area under the concentration- time curve over 24 hours
hCG Human Chorionic Gonadotropin
BMI Body mass index
BUN Blood urea nitrogen
Cmax Maximum observed concentration 
Cmin Minimum observed concentration
CÏ„ Last observed quantifiable concentration
CONSORT Consolidated Standards of Reporting Trials
CPK Creatine phosphokinase
CPMS Clinical Pharmacoki netics Modelling & Simulation
CRF Case Report Form
CV Coefficient of variance
DILI Drug Induced Liver Injury
DNA Deox yribonucleic acid
ECG Electrocardiogram
FDA Food and Drug Administration
FPFV First participant First Visit
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GCSP Global Clinical Safety  and Pharmacovigilence
GLP Good Laboratory  Practice
GSK GlaxoSmithKline
HBsAg Hepatitis B surface antigen
hCG Human chorionic gonadotropin
HDPE High densit y pol yethylene
HIV Human Immunodeficiency  Virus
HSR Hypersensitivity  Reactions
IB Investigatorâ€™s Brochure
ICF Informed consent form
ICH International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for 
Human Use
IDMC Independent Data Monitoring Committee
IDSL Integrated Data Standards L ibrary
IEC Independent Ethics Committee
IM Intramuscular
IND Investigational New Drug
2018N357118_01 CONFIDE NTIA L
208832
75IP Investigational Product
IRB Institutional Review Board
ISRs Injection Site Reactions 
IUD Intrauterine device
IUS Intrauterine hormone -releasing s ystem
ï¬z Terminal phase rate constant
L Liter
LA Long Acting
LFTs Liver function tests
Âµg Microgram
ÂµL Microliter
MCH Mean corpuscular hemoglobin
MCHC Mean corpuscular hemoglobin concentration
MCV Mean corpuscular volume
MedDRA Medical Dictionary  for Regulatory  Activities
Mg Milligrams
mL Milliliter
MSDS Material Safet y Data Sheet
msec Milliseconds
NNRTI Non-nucleoside re verse transcriptase inhibitor
OLI Oral Lead In
PCR Polymerase chain reaction
PD Pharmacod ynamic
PGx Pharmacogenetics
PK Pharmacokinetic
PoPPK Population PK
QC Quality  control
QD Once dail y
QTcB QT duration corrected for heart rate b y Bazettâ€™s formula
QTcF QT duration corrected for heart rate b y Fridericiaâ€™s 
formula
RAP Reporting and Anal ysis Plan
RBC Red blood cells
RNA Ribonucleic acid
RPV Rilpivirine
SAE Serious adverse event(s)
SARS -CoV2/ COVI D-19 Severe acute respiratory  syndrome coronavirus 2
SAS Statistical Analy sis Software
SC Subcutaneous
SD Standard deviation
SGOT Serum glutamic -oxaloacetic transaminase
SGPT Serum glutamic p yruvic transaminase
SoA Schedule of Activities
SOP Standard Operating Procedure
SRM Study  Reference Manual
STR Study  Team safet y & PKReview
2018N357118_01 CONFIDE NTIA L
208832
76SUSAR Suspected, Unexpected, Serious Adverse drug Reaction
tÂ½ Terminal phase half -life
Ï„ Dosing interval
tmax Time of occurrence of Cmax
UGT UDP glucuronosy ltransferase
ULN Upper limit of normal
VSL C ViiV Safet y and Labelling Committee
US United States
WBC White blood cells
WOCBP Woman of Childbearing Potential
Trademark Information
Trademarks of ViiV Healthcare Trademarks not owned by the ViiV 
Healthcare
None EDURANT
2018N357118_01 CONFIDE NTIA L
208832
7711.10. Appendix 10: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC).
DOCUMENT HISTORY
Document Date DNG Number
Amendment 1 13-AUG -2020 2018N357118_01
Original Protocol 02-MAR -2020 2018N357118_00
2018N357118_01 CONFIDE NTIA L
208832
7812. REFERENCES
ATLAS -2M: press release https://viivhealthcare.com/en- gb/media/press-
releases/2018/viiv- healthcare -reports -positive -48-week -results -for-first-pivotal- phase -iii-
study -for-novel -long-acting -injectable -hiv-treatment- regimen/
Chevat C, Viala -Dante M, et al. Development and p sychometric validation of a self -
administered questionnaire assessing the acceptance of influenza vaccination: the 
Vaccinees' Perception of Injection (VAPIÂ©) questionnaire. Health Qual Life Outcomes. 
2009; 7: 21.
Edurant Prescribing Information, June 2019.
Ford S, Margolis D, Chen S, Gould E, Spreen W. Plasma and tissue GSK1265744 
pharmacokinetics following long- acting parenteral administration in healthy  male and 
female subjects. Published at: I nternational Workshop on Clinical Pharmacology  of HIV 
Therap y 2013 - 14th Annual; April 22-24, 2013; Amsterdam, The Netherlands.
GlaxoSmithKline Document Number RH2009/00003/09: GSK1265744 (Cabotegravir) 
Clinical I nvestigator's Brochure, Version 09, December 2019.
Margolis D, Sutton K, Vente J, LeBlanc R et al. Long-Term Efficacy , Safet y and 
Durability  of CAB and RPV as Two Drug Oral Maintenance Therapy  â€“LATTE Week 
312 Result â€“IDWeek 2019 
Margolis DA, Gonzalez Garcia J, Stellbrink H- J, et al. Safet y, efficacy  and durability  of 
long-acting CAB and RPV as two drug IM maintenance therap y for HIV -1 infection:  
LATTE- 2 week 160 results. Presented at: HIV Drug Therapy  Glasgow 2018
NATAP report: R Verloes, G vanÃ”t Klooster, L Baert, F van Velsen,M- P Bouche, K 
Spittaels, J Leempoels, P Williams, G Kraus, P Wigerinck: TMC278 long acting -a 
parenteral nanosuspension formulation that provides sustained clinicall y relevant plasma 
concentratio ns in HIV -negative volunteers XVII International AIDS Conference, Mexico 
City August 2008 
Orkin C, Arasteh K, Hernandez -Mora MG, et al. Long -acting cabotegravir + rilpivirine as 
maintenance therap y: FLAI R week 48 results. Published at: Conference on Retr oviruses 
and Opportunistic Infections - 26th Annual; March 4 -7, 2019; Seattle, WA.
Rilpivirine Clinical I nvestigator Brochure [RPV IB], Edition Version 12 (18 -Jul-2019).
Rodger MA, King L. Drawing up and administering intramuscular injections: a review of 
the literature. J Adv Nurs. 2000;31(3):574-582.
Spreen W, Williams P, Ford SF, et al. Repeat dose co -administration of GSK1265744 
and TMC278 long -acting parenteral nanosuspensions: pharmacokinetics, safet y, and 
tolerability  in health y subjects. Published a t: International AIDS Society  2013 -7th 
Conference on HIV Pathogenesis, Treatment & Prevention; Jun 30 -July 3, 2013: Kuala 
Lumur, Malay sia.
2018N357118_01 CONFIDE NTIA L
208832
79Swindells S, Andrade- Villanueva J -F, Richmond G, et al. Long -acting cabotegravir + 
rilpivirine as maintenance therap y: ATLAS week 48 results. Published at: Conference on 
Retroviruses and Opportunistic I nfections - 26th Annual; March 4- 7, 2019; Seattle, WA.
World Health OrganisationMarch 2020: Global surveillanc e for COVID -19 caused b y 
human infection with COVID -19 virus. Interim guidance. Available at:
https://www.who.int/publications- detail/global -surveillance -for-human -infection -with-
novel -coronavirus- (2019 -ncov) . Accessed 18June 2020.